Alere 10-Q 14 Jun 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Jun. 12, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	ALR
Entity Registrant Name	ALERE INC.
Entity Central Index Key	1,145,460
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		87,368,721

Consolidated Statements of Oper

Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	[1]
Income Statement [Abstract]
Net product sales	$ 463,445	$ 468,502
Services revenue	122,129	115,709
Net product sales and services revenue	585,574	584,211
License and royalty revenue	2,642	2,729
Net revenue	588,216	586,940
Cost of net product sales	229,831	241,324
Cost of services revenue	75,899	73,100
Cost of net product sales and services revenue	305,730	314,424
Cost of license and royalty revenue	760	1,391
Cost of net revenue	306,490	315,815
Gross profit	281,726	271,125
Operating expenses:
Research and development	26,284	27,062
Sales and marketing	94,191	100,640
General and administrative	166,273	114,956
Impairment and gain on dispositions, net	0	(3,810)
Operating (loss) income	(5,022)	32,277
Interest expense, including amortization of original issue discounts and deferred financing costs	(43,183)	(42,106)
Other (expense) income, net	(2,516)	(1,349)
Loss from operations before provision (benefit) for income taxes	(50,721)	(11,178)
Provision (benefit) for income taxes	18,609	(172)
Loss from operations before equity earnings of unconsolidated entities, net of tax	(69,330)	(11,006)
Equity earnings of unconsolidated entities, net of tax	5,201	5,034
Net loss	(64,129)	(5,972)
Less: Net income attributable to non-controlling interests	183	103
Net loss attributable to Alere Inc. and Subsidiaries	(64,312)	(6,075)
Preferred stock dividends	(5,250)	(5,309)
Net loss available to common stockholders	$ (69,562)	$ (11,384)
Basic and diluted net loss per common share:
Net loss per common share	$ (0.80)	$ (0.13)
Weighted-average shares - basic and diluted	87,221	86,646
[1]	As Restated

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	[1]
Statement of Comprehensive Income [Abstract]
Net loss	$ (64,129)	$ (5,972)
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	53,330	22,193
Minimum pension liability adjustment	(71)	155
Other comprehensive income, before tax	53,259	22,348
Other comprehensive income	53,259	22,348
Comprehensive (loss) income	(10,870)	16,376
Less: Comprehensive income attributable to non-controlling interests	183	103
Comprehensive (loss) income attributable to Alere Inc. and Subsidiaries	$ (11,053)	$ 16,273
[1]	As Restated

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 601,472	$ 567,215
Restricted cash	53,143	51,550
Marketable securities	540	76
Accounts receivable, net of allowances of $75,976 and $75,798 at March 31, 2017 and December 31, 2016, respectively	387,687	413,535
Inventories, net	322,473	308,920
Prepaid expenses and other current assets	117,828	118,607
Total current assets	1,483,143	1,459,903
Property, plant and equipment, net	439,802	441,190
Goodwill	2,781,100	2,759,366
Other intangible assets with indefinite lives	22,118	27,164
Finite-lived intangible assets, net	785,065	805,577
Restricted cash	2,355	2,171
Other non-current assets	14,340	14,966
Investments in unconsolidated entities	79,227	72,225
Deferred tax assets	22,475	20,483
Non-current income tax receivable	44,244	45,234
Total assets	5,673,869	5,648,279
Current liabilities:
Short-term debt and current portion of long-term debt	82,506	82,370
Current portion of capital lease obligations	2,901	3,064
Accounts payable	211,430	195,879
Accrued expenses and other current liabilities	416,447	394,843
Total current liabilities	713,284	676,156
Long-term liabilities:
Long-term debt, net of current portion	2,852,326	2,858,205
Capital lease obligations, net of current portion	6,674	7,221
Deferred tax liabilities	120,826	119,098
Other long-term liabilities	160,136	155,992
Total long-term liabilities	3,139,962	3,140,516
Commitments and contingencies
Stockholders' equity:
Series B preferred stock, $0.001 par value (liquidation preference: $709,701 at March 31, 2017 and December 31, 2016); Authorized: 2,300 shares; Issued: 2,065 shares at March 31, 2017 and December 31, 2016; Outstanding: 1,774 shares at March 31, 2017 and December 31, 2016	606,406	606,406
Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 95,021 shares and 94,770 shares at March 31, 2017 and December 31, 2016, respectively; Outstanding: 87,342 shares and 87,091 shares at March 31, 2017 and December 31, 2016, respectively	95	95
Additional paid-in capital	3,474,861	3,474,979
Accumulated deficit	(1,671,431)	(1,607,119)
Treasury stock, at cost, 7,679 shares at March 31, 2017 and December 31, 2016	(184,971)	(184,971)
Accumulated other comprehensive loss	(409,139)	(462,398)
Total stockholders' equity	1,815,821	1,826,992
Non-controlling interests	4,802	4,615
Total equity	1,820,623	1,831,607
Total liabilities and equity	$ 5,673,869	$ 5,648,279

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 75,976	$ 75,798
Series B preferred stock, par value	$ 0.001	$ 0.001
Series B preferred stock, liquidation preference	$ 709,701	$ 709,701
Series B preferred stock, shares authorized	2,300,000	2,300,000
Series B preferred stock, shares issued	2,065,000	2,065,000
Series B preferred stock, shares outstanding	1,774,000	1,774,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	95,021,000	94,770,000
Common stock, shares outstanding	87,342,000	87,091,000
Treasury stock, shares	7,679,000	7,679,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended			15 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	[1]	Jul. 01, 2018
Cash Flows from Operating Activities:
Net loss	$ (64,129)	$ (5,972)
Adjustments to reconcile loss from operations to net cash (used in) provided by operating activities:
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	4,281	2,236
Depreciation and amortization	60,934	72,504
Non-cash stock-based compensation expense	10,363	9,602
Impairment of inventory	0	1,349
Impairment of long-lived assets	(342)	608
Loss on sale of fixed assets	2,341	323
Equity earnings of unconsolidated entities, net of tax	(5,201)	(5,034)
Deferred income taxes	(3,377)	(6,812)
Gain on business dispositions	0	(3,810)
Other non-cash items	1,564	2,496
Non-cash change in fair value of contingent consideration	489	142
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	33,105	(17,930)
Inventories, net	(19,272)	(10,284)
Prepaid expenses and other current assets	3,750	(5,775)
Accounts payable	13,363	(31,542)
Accrued expenses and other current liabilities	17,714	(5,182)
Other non-current assets and liabilities	5,652	35
Cash paid for contingent consideration	(159)	(143)
Net cash (used in) provided by operating activities	61,076	(3,189)
Cash Flows from Investing Activities:
Increase in restricted cash	(1,445)	(436)
Purchases of property, plant and equipment	(10,399)	(14,504)
Proceeds from sale of property, plant and equipment	139	612
Cash received from business disposition, net of cash divested	0	21,470
Cash paid for business acquisitions, net of cash acquired	(3,060)	(5,945)
Cash received from sales of marketable securities	(7)	93
Cash received from equity method investments	0	2,205
Cash paid for equity investments	(232)	(184)
Proceeds from sale of equity investments	229	0
Increase (decrease) in other assets	82	(540)
Net cash (used in) provided by investing activities	(14,693)	2,771
Cash Flows from Financing Activities:
Cash paid for financing costs	0	(1)
Cash paid for contingent consideration	(128)	(145)
Proceeds from issuance of common stock, net of issuance costs	496	11,124
Proceeds from issuance of long-term debt	0	325
Payments on long-term debt	(10,158)	(17,275)
Net proceeds (payments) under revolving credit facilities	48	(127)
Cash paid for dividends	(5,323)	(5,323)
Cash paid for employee taxes related to shares withheld	(5,601)	(1,410)
Principal payments on capital lease obligations	(852)	(1,107)
Net cash used in financing activities	(21,518)	(13,939)
Foreign exchange effect on cash and cash equivalents	9,392	2,820
Net increase (decrease) in cash and cash equivalents	34,257	(11,537)
Cash and cash equivalents, beginning of period	567,215	502,200		$ 601,472
Cash and cash equivalents, end of period	$ 601,472	$ 490,663
[1]	As Restated

Basis of Presentation of Financ

Basis of Presentation of Financial Information	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation of Financial Information	(1) Basis of Presentation of Financial Information The accompanying consolidated financial statements of Alere Inc. are unaudited. In the opinion of management, the unaudited consolidated financial statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, for interim financial information and in accordance with the instructions to Form 10-Q Regulation S-X. Form 10-K Our operating segments are currently (i) professional diagnostics; (ii) consumer diagnostics; and (iii) other non-reportable. 10-K 10-K 10-Q, non-reportable pre-established The consolidated financial statements include the accounts of Alere Inc. and its subsidiaries. Intercompany transactions and balances are eliminated and net earnings are reduced by the portion of the net earnings of subsidiaries applicable to non-controlling interests. Certain amounts presented may not recalculate directly, due to rounding.

Restatement of Previously Issue

Restatement of Previously Issued Financial Statements	3 Months Ended
	Mar. 31, 2017
Accounting Changes and Error Corrections [Abstract]
Restatement of Previously Issued Financial Statements	(2) Restatement of Previously Issued Financial Statements On April 12, 2017, management and the Audit Committee of our Board of Directors concluded that our financial statements as of December 31, 2015 and 2014 and for each of the years ended December 31, 2015, 2014 and 2013, and for each of the quarterly and year-to-date year-to-date In our Annual Report on Form 10-K year-to-date year-to-date Form 10-Q The Restatement was the result of the failure to correctly apply U.S. GAAP regarding the timing of revenue recognition primarily related to transactions in which we recognized revenue prior to full satisfaction of all contractual criteria for title and risk of loss passing to the customer as required by U.S. GAAP. The principal cause of these misstatements in the timing of revenue recognition is attributable to inappropriate conduct at our Standard Diagnostics subsidiary. These misstatements were primarily the result of conduct and practices initiated by a former employee in the sales organization. The inappropriate conduct and practices involved, among other things, misrepresentation and/or fabrication of documents used to validate revenue recognition that were intentionally concealed from our senior leadership team and our external auditors at the time of the transactions and during the global revenue recognition assessment conducted as part of the filing of the Annual Report on Form 10-K 10-Q The following schedules reconcile the amounts as previously reported in the applicable financial statements as filed with the Securities and Exchange Commission (prior to the Restatement) to the corresponding restatement amounts for the three months ended March 31, 2016: ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended March 31, 2016 As Previously Restatement As Restated Net product sales $ 459,771 $ 8,731 $ 468,502 Services revenue 115,709 — 115,709 Net product sales and services revenue 575,480 8,731 584,211 License and royalty revenue 2,729 — 2,729 Net revenue 578,209 8,731 586,940 Cost of net product sales 237,461 3,863 241,324 Cost of services revenue 73,100 — 73,100 Cost of net product sales and services revenue 310,561 3,863 314,424 Cost of license and royalty revenue 1,391 — 1,391 Cost of net revenue 311,952 3,863 315,815 Gross profit 266,257 4,868 271,125 Operating expenses: — Research and development 27,062 — 27,062 Sales and marketing 99,813 827 100,640 General and administrative 114,956 — 114,956 Impairment and (gain) loss on dispositions, net (3,810 ) — (3,810 ) Operating income 28,236 4,041 32,277 Interest expense, including amortization of original issue discounts and deferred financing costs (42,106 ) — (42,106 ) Other (expense) income, net (1,349 ) — (1,349 ) Loss from operations before provision (benefit) for income taxes (15,219 ) 4,041 (11,178 ) Provision (benefit) for income taxes (208 ) 36 (172 ) (Loss) income from operations before equity earnings of unconsolidated entities, net of tax (15,011 ) 4,005 (11,006 ) Equity earnings of unconsolidated entities, net of tax 5,034 — 5,034 Net (loss) income (9,977 ) 4,005 (5,972 ) Less: Net income attributable to non-controlling 103 — 103 Net (loss) income attributable to Alere Inc. and Subsidiaries (10,080 ) 4,005 (6,075 ) Preferred stock dividends (5,309 ) — (5,309 ) Net (loss) income available to common stockholders $ (15,389 ) $ 4,005 $ (11,384 ) Basic and Diluted net income (loss) per common share: Net (loss) income per common share $ (0.18 ) $ 0.05 $ (0.13 ) Weighted-average shares —basic and diluted 86,646 — 86,646 (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. Three Months Ended March 31, 2016 As Previously Restatement As Restated Comprehensive income attributable to Alere Inc. and Subsidiaries $ 12,268 $ 4,005 $ 16,273 (1) The restatement adjustment to total comprehensive income (loss) attributable to Alere Inc. and Subsidiaries is comprised solely of the restatement adjustment to net income (loss) for the period. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, except per share amounts) (unaudited) Three Months Ended March 31, 2016 As Previously Restatement As Restated Cash Flows from Operating Activities: Net loss $ (9,977 ) $ 4,005 $ (5,972 ) Adjustments to reconcile loss from operations to net cash (used in) provided by operating activities: Non-cash 2,236 — 2,236 Depreciation and amortization 72,504 — 72,504 Non-cash 9,602 — 9,602 Impairment of inventory 1,349 — 1,349 Impairment of long-lived assets 608 — 608 Loss on sale of fixed assets 323 — 323 Equity earnings of unconsolidated entities, net of tax (5,034 ) — (5,034 ) Deferred income taxes (6,812 ) — (6,812 ) Gain on business dispositions (3,810 ) — (3,810 ) Other non-cash 2,496 — 2,496 Non-cash 142 — 142 Changes in assets and liabilities, net of acquisitions: Accounts receivable, net (9,199 ) (8,731 ) (17,930 ) Inventories, net (14,147 ) 3,863 (10,284 ) Prepaid expenses and other current assets (5,796 ) 21 (5,775 ) Accounts payable (31,542 ) — (31,542 ) Accrued expenses and other current liabilities (6,003 ) 821 (5,182 ) Other non-current 14 21 35 Cash paid for contingent consideration (143 ) — (143 ) Net cash (used in) provided by operating activities (3,189 ) — (3,189 ) Cash Flows from Investing Activities: Increase in restricted cash (436 ) — (436 ) Purchases of property, plant and equipment (14,504 ) — (14,504 ) Proceeds from sale of property, plant and equipment 612 — 612 Cash received from business disposition, net of cash divested 21,470 — 21,470 Cash paid for business acquisitions, net of cash acquired (5,945 ) — (5,945 ) Cash received from sales of marketable securities 93 — 93 Cash received from equity method investments 2,205 — 2,205 Cash paid for equity investments (184 ) — (184 ) Decrease in other assets (540 ) — (540 ) Net cash (used in) provided by investing activities 2,771 — 2,771 Cash Flows from Financing Activities: Cash paid for financing costs (1 ) — (1 ) Cash paid for contingent consideration (145 ) — (145 ) Proceeds from issuance of common stock, net of issuance costs 11,124 — 11,124 Proceeds from issuance of long-term debt 325 — 325 Payments on long-term debt (17,275 ) — (17,275 ) Net payments under revolving credit facilities (127 ) — (127 ) Cash paid for dividends (5,323 ) — (5,323 ) Cash paid for employee taxes related to shares withheld (1,410 ) — (1,410 ) Principal payments on capital lease obligations (1,107 ) — (1,107 ) Net cash used in financing activities (13,939 ) — (13,939 ) Foreign exchange effect on cash and cash equivalents 2,820 — 2,820 Net decrease in cash and cash equivalents (11,537 ) — (11,537 ) Cash and cash equivalents, beginning of period 502,200 — 502,200 Cash and cash equivalents, end of period $ 490,663 $ — $ 490,663 (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and such amounts have been revised from the figures presented in such Quarterly Report on Form 10-Q as a result of the retrospective adoption of ASU 2016-09, which reclassified $1,410 of employee taxes related to shares withheld from operating activities to financing activities. (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the misstatements in the classification of certain amounts between current assets, noncurrent assets and current liabilities.

Merger Agreement

Merger Agreement	3 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Merger Agreement	(3) Merger Agreement Merger Agreement with Abbott Laboratories On January 30, 2016, we entered into an Agreement and Plan of Merger, or the Merger Agreement, with Abbott Laboratories, or Abbott. The Merger Agreement provides for the merger of a wholly owned subsidiary of Abbott with and into Alere, or the merger, with Alere surviving the merger as a wholly owned subsidiary of Abbott, or the surviving corporation. Under the terms of the Merger Agreement, prior to its amendment (as described herein), holders of shares of our common stock were entitled to receive $56.00 in cash, without interest, in exchange for each share of common stock. On April 13, 2017, Abbott and Alere entered into an Amendment to Agreement and Plan of Merger, or the Merger Agreement Amendment, which amends the Merger Agreement (as amended by the Merger Agreement Amendment, the Amended Merger Agreement), which provides, among other things, that the holders of shares of our common stock will receive $51.00 in cash, without interest, in exchange for each share of common stock. Other than as expressly modified pursuant to the Merger Agreement Amendment, the Merger Agreement remains in full force and effect. The Amended Merger Agreement has been approved by our Board of Directors. Each share of our Series B Preferred Stock issued and outstanding immediately prior to the effective time of the merger will remain issued and outstanding immediately following the consummation of the merger as one share of Series B Convertible Preferred Stock, par value $0.001 per share, of the surviving corporation. Completion of the merger pursuant to the Amended Merger Agreement is subject to customary closing conditions, including (1) the adoption of the Amended Merger Agreement by the affirmative vote of the holders of at least a majority of all outstanding shares of our common stock, (2) there being no judgment or law enjoining or otherwise prohibiting the consummation of the merger, (3) the expiration of the waiting period applicable to the merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or the HSR Act, and receipt of other required antitrust approvals and (4) the absence of a Material Adverse Effect (as defined in the Amended Merger Agreement). Under the terms of the Amended Merger Agreement, Abbott has agreed to make certain divestitures if necessary to obtain the consent of the antitrust authorities to the transaction contemplated by the Amended Merger Agreement, subject to certain exceptions set forth in the Amended Merger Agreement. The obligation of each of the parties to consummate the merger is also conditioned on the other party’s representations and warranties being true and correct (subject to certain materiality exceptions) and the other party having performed in all material respects its obligations under the Amended Merger Agreement. The Amended Merger Agreement contains certain termination rights that allow the Amended Merger Agreement to be terminated in certain circumstances. In addition, the Merger Agreement Amendment extends the date after which each of Alere and Abbott would have a right to terminate the Amended Merger Agreement to September 30, 2017, subject to the terms and conditions set forth in the Amended Merger Agreement. The Merger Agreement Amendment reduces the termination fee that Alere may be required to pay Abbott under specified circumstances to $161 million, from $177 million. The Merger Agreement Amendment also provides that neither any matter set forth in our public filings made with the Securities and Exchange Commission, or SEC, between January 1, 2014 and April 13, 2017, nor any matter of which Abbott or any of Abbott’s representatives was made aware prior to April 13, 2017, could be taken into account in determining whether a Material Adverse Effect has occurred or would reasonably be expected to occur. Further, in addition to the qualifications set forth in the original Merger Agreement, the Amendment qualifies all of our representations and warranties made in the Amended Merger Agreement (including those made in the original Merger Agreement) by all matters set forth in our public filings made with the SEC between January 1, 2014 and April 13, 2017 and any matter known by Abbott or any of Abbott’s representatives prior to April 13, 2017. In addition, the Merger Agreement Amendment changes Abbott’s commitment to provide Alere’s employees that continue with Abbott with specified levels of compensation and benefits to be a commitment through the first anniversary of the closing of the merger, rather than through December 31, 2017 and a 2018 long-term incentive award to each continuing employee employed by Abbott or its subsidiaries at the time annual long-term awards are made generally that is no less favorable than the long-term incentive award made to similarly situated employees of Abbott generally. Antitrust Clearance On May 2, 2016, Abbott and Alere received a request for additional information, or a “second request,” from the United States Federal Trade Commission, or the FTC, relating to Abbott’s potential acquisition of Alere. The second request was issued under the HSR Act. In addition, Abbott has agreed voluntarily to provide the FTC at least 60 days advance notice before certifying substantial compliance with the second request and to extend the waiting period imposed by the HSR Act to not less than 60 days after Abbott and Alere have certified substantial compliance with the second request, unless the period is further extended voluntarily by the parties or terminated sooner by the FTC. On June 23, 2016, Abbott and Alere received a request for additional information, or a “supplemental information request,” from the Canadian Competition Bureau, or the Bureau, relating to Abbott’s potential acquisition of Alere. The supplemental information request was issued under the Competition Act of Canada, or the Competition Act. The effect of the supplemental information request is to extend the waiting period imposed by the Competition Act until 30 days after Abbott and Alere have each complied with the supplemental information request, unless the period is extended voluntarily by the parties or terminated sooner by the Bureau. On June 8, 2017, the Bureau notified the parties that it will be requiring a Canadian consent agreement requiring the divestiture of the epoc and Triage product lines. The purchasers and terms of sale need to be approved by the Bureau. On January 25, 2017, the European Commission approved the merger under the EU Merger Regulation. The approval is conditional on, and the merger may not be completed until, Abbott has entered into binding agreements to divest the epoc and Triage product lines, as well as Alere’s activities relating to the commercialization of BNP assays for use on Beckman-Coulter laboratory analyzers, to one or more purchasers. The purchasers and terms of sale need to be approved by the European Commission. As of the date of the filing of this Quarterly Report on Form 10-Q, On April 20, 2017, the South Korean antitrust authority informed Abbott that it would be expanding its review period by 90 days. As of the date of the filing of this Quarterly Report on Form 10-Q, In connection with the divestiture of any of these businesses, we may need to enter into amendments to existing agreements or enter into new agreements to facilitate such divestitures. The terms of such amendments or new agreements may relate to, among other things, existing agreements with customers to purchase our products or may relate to the amendment to the agreements under which we initially acquired these businesses, including amendments to unresolved earn-out payment provisions. Any such agreement or amendment may require that we negotiate new terms and conditions with customers or with the previous owners of the business, and such terms may not be as advantageous to us as the current contracts or we may require that we incur material charges in connection with such amendments or agreements. For information relating to the litigation with Abbott and the Settlement Agreement with Abbott, see Note 15(b).

Cash and Cash Equivalents

Cash and Cash Equivalents	3 Months Ended
	Mar. 31, 2017
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	(4) Cash and Cash Equivalents We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At March 31, 2017, our cash equivalents consisted of money market funds.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Inventories	(5) Inventories Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): March 31, 2017 December 31, 2016 Raw materials $ 103,838 $ 97,652 Work-in-process 68,471 69,086 Finished goods 150,164 142,182 $ 322,473 $ 308,920

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	(6) Stock-based Compensation We recorded stock-based compensation expense in our consolidated statements of operations for the three months ended March 31, 2017 and 2016 as follows (in thousands): Three Months Ended March 31, 2017 2016 Cost of net revenue $ 396 $ 479 Research and development 384 398 Sales and marketing 1,854 1,925 General and administrative 7,729 6,800 10,363 9,602 Benefit for income taxes 493 — Stock-based compensation, net of tax $ 10,856 $ 9,602

Net Loss per Common Share

Net Loss per Common Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Net Loss per Common Share	(7) Net Loss per Common Share The following table sets forth the computation of basic and diluted net loss per common share for the three months ended March 31, 2017 and 2016 (in thousands, except per share amounts): Three Months Ended March 31, 2017 2016 (As Basic and diluted net loss per common share: Numerator: Loss from operations $ (64,129 ) $ (5,972 ) Preferred stock dividends (5,250 ) (5,309 ) Loss from operations attributable to common shares (69,379 ) (11,281 ) Less: Net income attributable to non-controlling 183 103 Net loss available to common stockholders $ (69,562 ) (11,384 ) Denominator: Weighted-average common shares outstanding – basic and diluted 87,221 $ 86,646 Basic and diluted net loss per common share: Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries $ (0.80 ) $ (0.13 ) The following potential dilutive securities were not included in the calculation of diluted net loss per common share because the inclusion thereof would be antidilutive (in thousands): Three Months Ended March 31, 2017 2016 Denominator: Options to purchase shares of common stock 6,322 7,378 Conversion shares related to 3% convertible senior subordinated notes — 3,411 Conversion shares related to Series B convertible preferred stock 10,238 10,239 Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding 16,560 21,028

Stockholders' Equity and Non-Co

Stockholders' Equity and Non-Controlling Interests	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Stockholders' Equity and Non-Controlling Interests	(8) Stockholders’ Equity and Non-Controlling (a) Preferred Stock For both the three months ended March 31, 2017 and 2016, Series B preferred stock dividends amounted to $5.3 million, which reduced earnings available to common stockholders for purposes of calculating net loss per common share for each of these periods. As of March 31, 2017, $5.3 million of Series B preferred stock dividends was accrued. As of April 15, 2017, payments have been made with respect to all dividends through March 31, 2017. The Series B preferred stock dividends for the three months ended March 31, 2017 and 2016 were paid in cash in the subsequent quarters. (b) Changes in Stockholders’ Equity and Non-Controlling A summary of the changes in stockholders’ equity and non-controlling Three Months Ended March 31, 2017 Total Stockholders’ Equity Non- controlling Interests Total Equity Equity, beginning of period $ 1,826,992 $ 4,615 $ 1,831,607 Issuance of common stock under employee compensation plans 424 — 424 Surrender of common stock to settle taxes on restricted stock units (5,582 ) — (5,582 ) Preferred stock dividends (5,323 ) — (5,323 ) Stock-based compensation expense 10,363 — 10,363 Other adjustments — 4 4 Net income (loss) (64,312 ) 183 (64,129 ) Total other comprehensive income 53,259 — 53,259 Equity, end of period $ 1,815,821 $ 4,802 $ 1,820,623

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Business Combinations	(9) Business Combinations Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner. Net assets acquired are recorded at their estimated fair value and are subject to adjustment upon finalization of the fair value analysis. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized. (a) Acquisition in 2016 EDTS On February 11, 2016, we acquired all of the outstanding shares of European Drug Testing Services EDTS AB, or EDTS, located in Lidingo, Sweden, a provider of services related to on-site Our consolidated statements of operations for the three months ended March, 31, 2017 and 2016 included revenue totaling approximately $1.6 million and $0.9 million, respectively, related to this business. Goodwill has been recognized in the acquisition and amounted to approximately $2.1 million, which is not deductible for tax purposes. A summary of the fair values of the net assets acquired from EDTS is as follows (in thousands): Fair Value Current assets $ 1,371 Property, plant and equipment 115 Goodwill 2,060 Intangible assets 4,220 Total assets acquired $ 7,766 Current liabilities $ 368 Non-current 928 Total liabilities assumed $ 1,296 Net assets acquired $ 6,470 Cash paid $ 6,470 The following table provides information regarding the intangible assets acquired in connection with the EDTS acquisition and their respective fair values and weighted-average useful lives (dollars in thousands): Fair Value Weighted- average Useful Life Core technology and patents $ 540 10.0 years Trademarks and trade names 310 20.0 years Customer relationships 2,800 14.0 years Non-compete 570 3.0 years Total intangible assets $ 4,220

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2017
Restructuring and Related Activities [Abstract]
Restructuring	(10) Restructuring The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three months ended March 31, 2017 and 2016 (in thousands): Three Months Ended March 31, Statement of Operations Caption 2017 2016 Cost of net revenue $ 815 $ 1,267 Research and development 127 1,920 Sales and marketing 10 650 General and administrative 2,078 3,826 Total operating expenses 3,030 7,663 Interest expense, including amortization of original issue discounts and deferred financing costs 1 5 Total charges $ 3,031 $ 7,668 (a) Restructuring Plans During 2016, management developed world-wide cost reduction plans to reduce costs and improve operational efficiencies within our professional diagnostics and corporate and other business segments, primarily impacting our manufacturing and supply chain, and research and development groups, as well as closing certain business locations in Europe and the United States. The following table summarizes the restructuring activities, for the three months ended March 31, 2017 and 2016 and since inception for all restructuring plans adopted by us, including the 2016 restructuring plans. Our restructuring plans are disclosed in Note 23 to the condensed consolidated financial statements included in our Annual Report on Form 10-K Three Months Ended March 31, Since 2017 2016 Inception Professional Diagnostics Severance-related costs $ 678 $ 3,091 $ 48,101 Facility and transition costs 443 981 16,378 Other exit costs 1 5 834 Cash charges 1,122 4,077 65,313 Fixed asset and inventory impairments — 398 17,951 Other non-cash — 213 2,160 Total professional diagnostics charges $ 1,122 $ 4,688 $ 85,424 Corporate and Other Severance-related costs $ 1 $ 15 $ 4,624 Facility and transition costs 1,908 2,965 34,879 Total corporate and other charges $ 1,909 $ 2,980 $ 39,503 Total restructuring charges $ 3,031 $ 7,668 $ 124,927 We anticipate incurring approximately $12.9 million in additional costs under our 2016 restructuring plans related to our professional diagnostics and corporate and other business segments, primarily related to integration and operational initiatives related to our international supply chain. We may develop additional restructuring plans over the remainder of 2017 and beyond. In addition, we anticipate incurring approximately $2.3 million in additional costs under earlier restructuring plans related to our professional diagnostics and corporate and other business segments, primarily related to the closure of our manufacturing facility in Israel. (b) Restructuring Reserves The following table summarizes our restructuring reserves related to the plans described above, of which $6.4 million is included in accrued expenses and other current liabilities and $0.3 million is included in other long-term liabilities on our accompanying consolidated balance sheets (in thousands): Severance- Facility and Other Exit Total Balance, December 31, 2016 $ 3,339 $ 7,512 $ 39 $ 10,890 Charges 679 2,351 1 3,031 Payments (766 ) (6,443 ) (40 ) (7,249 ) Currency adjustments 15 20 — 35 Balance, March 31, 2017 $ 3,267 $ 3,440 $ — $ 6,707

Long-term Debt

Long-term Debt	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Long-term Debt	(11) Long-term Debt We had the following long-term debt balances outstanding as of March 31, 2017 and December 31, 2016 (in thousands): March 31, 2017 December 31, 2016 A term loans (1)(2)(3) $ 538,372 $ 544,745 B term loans (1)(2)(3) 950,756 952,664 Revolving loans (1)(2)(3) 125,000 125,000 7.25% Senior notes (2)(3)(4) 443,924 442,709 6.5% Senior subordinated notes (2)(3) 415,813 415,102 6.375% Senior subordinated notes (2)(3) 413,300 412,831 Other lines of credit 1,202 1,124 Other 46,465 46,400 2,934,832 2,940,575 Less: Short-term debt and current portion of long-term debt (82,506 ) (82,370 ) Long-term debt $ 2,852,326 $ 2,858,205 (1) Incurred under our secured credit facility entered into on June 18, 2015. (2) As discussed more fully in Item 2. “ Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources, 10-K 10-Q Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources, Form 10-Q Form 10-Q 10-Q (3) As discussed more fully below, due to our failure to timely file our Annual Report on Form 10-K Form 10-K (4) The 7.25% senior notes mature on July 1, 2018, unless earlier redeemed. Upon maturity, we will be required to pay the principal amount of $450 million, plus all accrued and unpaid interest. Management expects that the acquisition of Alere by Abbott pursuant to the terms of the Amended Merger Agreement will take place prior to the maturity date of July 1, 2018 and, if this expectation is correct, the holders of the 7.25% senior notes will have the rights set forth in connection with such transaction as set forth below in this paragraph. In the event that the transactions contemplated by the Amended Merger Agreement do not close, we expect that we would be able to pay such principal and accrued interest by one or a combination of the following: refinancing such indebtedness as we have done in the past, using available cash resources, or utilizing amounts available under the revolving credit facility. If a change of control occurs, subject to specified conditions, we must give holders of the 7.25% senior notes an opportunity to sell their notes to us at a purchase price of 101% of the principal amount of the notes, plus accrued and unpaid interest to (but excluding) the date of the purchase. The merger under the Amended Merger Agreement, as described in Note 3 above will, if consummated, constitute a change of control under the indenture governing the 7.25% senior notes. In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for the three months ended March 31, 2017 and 2016 as follows (in thousands): Three Months Ended March 31, 2017 2016 Secured credit facility (1)(2) $ 18,730 $ 17,043 7.25% Senior notes (2) 9,372 8,524 6.375% Senior subordinated notes (2) 7,242 7,003 6.5% Senior subordinated notes (2) 7,617 7,231 3% Convertible senior subordinated notes — 1,244 Other 222 1,061 $ 43,183 $ 42,106 (1) Includes “A” term loans, “B” term loans, and revolving line of credit loans. (2) For the three months ended March 31, 2017, the amounts include $2.1 million related to the amortization of fees paid for certain debt modifications, of which there were none in the same period of 2016. April 2017 Amendment to Credit Facility On April 24, 2017, we entered into a Third Amendment to the Credit Agreement for our secured credit facility, dated as of June 18, 2015, among the Company, the several lenders from time to time party thereto, the Administrative Agents (as defined in the Credit Agreement) and certain other agents and arrangers. Pursuant to the Third Amendment, the lenders under the Credit Agreement have agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or may occur after April 24, 2017, resulting from, among other things, (x) our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) the financial statements and the related deliverables for the fiscal year ended December 31, 2016 by the applicable deadline under the Credit Agreement, (y) any restatement, revision or other adjustment of certain financial statements as a result of our review described in our Current Report on Form 8-K 8-K, 8-K, May 2017 Consent Solicitation for Notes On May 1, 2017, we commenced consent solicitations relating to the Notes. On May 4, 2017, we made certain modifications to the consent solicitations, which are reflected herein. We solicited consents from holders of each series of Notes to extend the deadline for delivery of certain financial information and to waive through and until 5:00 p.m., New York City time, on June 15, 2017, any default or event of default that occurred, is continuing or may occur under the indentures under which the Notes were issued (and its consequences) in connection with any failure to timely file with the SEC or to timely furnish to the relevant trustees pursuant to the indentures, our Annual Report on Form 10-K 10-K 10-K Form 10-K May 2017 Amendment to Credit Facility On May 30, 2017, we entered into a fourth amendment to the Credit Agreement pursuant to which the lenders under the Credit Agreement agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or occur after May 30, 2017, resulting from, among other things, (x) failure to deliver to the Administrative Agents (as defined in the Credit Agreement) the financial statements and the related deliverables for the fiscal year ended December 31, 2016 and the fiscal quarter ended March 31, 2017, in each case, by the applicable deadlines under the Credit Agreement, (y) any restatement, revision or other adjustment of certain financial statements as a result of the Company’s review described in our Current Report on Form 8-K May 8-K, 8-K, June 2017 Consent Solicitation for Notes On June 1, 2017, we commenced consent solicitations relating to each series of our Notes. We solicited consents from holders of each series of Notes to further extend the deadline for delivery of certain financial information and to waive, in each case (i) through and until 5:00 p.m., New York City time, on August 4, 2017 (such time and date, the “First Waiver Date”), (ii) through and until 5:00 p.m., New York City time, on September 5, 2017 (such time and date, the “Second Waiver Date”) if uncured immediately prior to the First Waiver Date, and (iii) through and until 5:00 p.m., New York City time, on October 4, 2017 (such time and date, the “Third Waiver Date”) if uncured immediately prior to the Second Waiver Date, any default or event of default that occurred, is continuing or may occur under the indentures (and its consequences) in connection with any failure to timely file with the SEC or to timely furnish to the relevant trustees pursuant to the indentures, the 2016 Form 10-K 10-Q 10-K As of March 31, 2017, other than with respect to the delayed delivery of SEC filings for the fiscal year ended December 31, 2016 and the quarter ended March 31, 2017 and related deliverables as described in the preceding paragraphs, we were in compliance with all of our obligations and covenants under the Credit Agreement and the indentures governing our Notes.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	(12) Fair Value Measurements We apply fair value measurement accounting to value our financial assets and liabilities. Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. Described below are the three levels of inputs that may be used to measure fair value: Level 1— Level 2— Level 3— The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2017 and December 31, 2016, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): Description March 31, 2017 Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 540 $ 540 $ — $ — Total assets $ 540 $ 540 $ — $ — Liabilities: Contingent consideration obligations (1) $ 43,400 $ — $ — $ 43,400 Total liabilities $ 43,400 $ — $ — $ 43,400 Description December 31, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 76 $ 76 $ — $ — Total assets $ 76 $ 76 $ — $ — Liabilities: Contingent consideration obligations (1) $ 43,200 $ — $ — $ 43,200 Total liabilities $ 43,200 $ — $ — $ 43,200 (1) We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out earn-out Commitments and Contingences Changes in the fair value of our Level 3 contingent consideration obligations during the three months ended March 31, 2017 were as follows (in thousands): Fair value of contingent consideration obligations, December 31, 2016 $ 43,200 Payments (287 ) Fair value adjustments 489 Foreign currency adjustments (2 ) Fair value of contingent consideration obligations, March 31, 2017 $ 43,400 At March 31, 2017 and December 31, 2016, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values. The carrying amount and estimated fair value of our long-term debt (including the current portion) were $2.9 billion and $3.0 billion, respectively, at March 31, 2017. The carrying amount and estimated fair value of our long-term debt (including the current portion) were, in each case, $2.9 billion at December 31, 2016. The estimated fair value of our long-term debt was determined using information derived from available market sources (Level 2 in the fair value hierarchy), including open-market trades and market quotes observed at or near period end, and may not be representative of actual values that could have been or will be realized in the future.

Financial Information by Segmen

Financial Information by Segment	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Financial Information by Segment	(13) Financial Information by Segment Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and members of senior management. Our operating segments are currently (i) professional diagnostics; (ii) consumer diagnostics; and (iii) other non-reportable. 10-K 10-K non-reportable pre-established 10-Q Our operating results include license and royalty revenue which are allocated to professional diagnostics and consumer diagnostics on the basis of the original license or royalty agreement. We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three months ended March 31, 2017 and 2016 is as follows (in thousands): Professional Consumer Other Non- Reportable Corporate Total Three Months Ended March 31, 2017: Net revenue $ 534,317 $ 17,240 $ 36,659 $ — $ 588,216 Operating income (loss) $ 88,957 $ 71 $ 6,616 $ (100,666 ) $ (5,022 ) Depreciation and amortization $ 54,289 $ 1,155 $ 3,188 $ 2,302 $ 60,934 Restructuring charge $ 1,122 $ — $ — $ 1,909 $ 3,031 Stock-based compensation $ — $ — $ — $ 10,363 $ 10,363 Professional Consumer Other Non- Reportable Corporate Total Three Months Ended March 31, 2016: Net revenue, as restated $ 534,513 $ 17,442 $ 34,985 $ — $ 586,940 Operating income (loss), as restated $ 80,356 $ 167 $ 6,238 $ (54,484 ) $ 32,277 Depreciation and amortization $ 63,673 $ 1,499 $ 5,159 $ 2,173 $ 72,504 Restructuring charge $ 4,688 $ — $ — $ 2,980 $ 7,668 Stock-based compensation $ — $ — $ — $ 9,602 $ 9,602 Assets: As of March 31, 2017 $ 5,170,280 $ 177,686 $ 88,366 $ 237,537 $ 5,673,869 As of December 31, 2016 $ 5,199,806 $ 175,362 $ 87,193 $ 185,918 $ 5,648,279 The following table summarizes our net revenue from the professional diagnostics reporting segment by groups of similar products and services for the three months ended March 31, 2017 and 2016 (in thousands): Three Months Ended March 31, 2017 2016 (As Restated) Cardiometabolic $ 125,176 $ 159,663 Infectious disease 222,934 191,956 Toxicology 150,637 146,783 Other 32,928 33,382 Total professional diagnostics net product sales and services revenue 531,675 531,784 License and royalty revenue 2,642 2,729 Total professional diagnostics net revenue $ 534,317 $ 534,513

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	(14) Related Party Transactions (a) SPD Joint Venture In May 2007, we completed the formation of SPD Swiss Precision Diagnostics GmbH, or SPD, our 50/50 joint venture with Procter & Gamble, or P&G, for the development, manufacturing, marketing and sale of existing and to-be-developed We had a net payable to SPD of $4.7 million as of March 31, 2017 and $3.7 million as of December 31, 2016. The $4.7 million net payable balance as of March 31, 2017 is net of a receivable of approximately $1.2 million for costs incurred in connection with our 2008 SPD-related SPD-related SPD-related Under the terms of our product supply agreement, SPD purchases products from our manufacturing facilities in China. SPD in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged, a portion of the tests are sold to P&G for distribution to third-party customers in North America. We defer our profit on products sold to SPD until the products are sold through to the customer. The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): Balance Sheet Caption March 31, 2017 December 31, 2016 Accounts receivable, net of allowances $ 7,104 $ 7,855 Prepaid expenses and other current assets $ 8,231 $ 7,486 Other non-current $ 6,228 $ 6,122 Accounts payable $ 32,413 $ 34,216 As previously disclosed, SPD is currently involved in civil litigation brought by a competitor in the United States with respect to the advertising of one of SPD’s products in the United States. The district court issued an injunction with respect to sales and advertising of such product and determined that SPD violated certain laws with respect to the advertising of such product. SPD’s appeal of this decision was unsuccessful. The competitor’s request for damages is now pending before the district court. In addition, a class action lawsuit was filed against SPD and P&G in the United States District Court for the Central District of California alleging violations of certain laws in connection with the sales and advertising of one of SPD’s products, which claims are based on similar grounds as those described above. On August 19, 2016, the class action lawsuit was dismissed with prejudice. The plaintiffs appealed the district court’s decision but, on March 30, 2017, the case was voluntarily dismissed upon initiation of the plaintiff. There may be additional lawsuits against SPD or us relating to this matter in the future. The ultimate resolution of the matter, including the amount of any damages that may be required to be paid, is not known at this time, nor is the potential impact that any pending litigation or future litigation may have on SPD or us, including whether any such resolution or any damages imposed by a court would have a material adverse impact on SPD and, ultimately, by virtue of our 50% interest in SPD, on our financial position or results of operations. (b) Entrustment Loan Arrangement with SPD Shanghai Our subsidiary Alere (Shanghai) Diagnostics Co., Ltd., or Alere Shanghai, and SPD’s subsidiary SPD Trading (Shanghai) Co., Ltd., or SPD Shanghai, entered into an entrustment loan arrangement for a maximum of CNY 23.0 million (approximately $3.3 million at March 31, 2017), in order to finance the latter’s short-term working capital needs, with the HSBC Shanghai Branch, or HSBC. The agreement governs the setting up of an Entrustment Loan Account with HSBC, into which Alere Shanghai deposits certain monies. This restricted cash account provides a guarantee to HSBC of amounts borrowed from HSBC by SPD Shanghai. The Alere Shanghai HSBC account is recorded as restricted cash on our balance sheet and amounted to $3.3 million at March 31, 2017. (c) TechLab On September 16, 2016, we sold our 49% interest in TechLab Inc., a company that provides diagnostic testing products used by physicians and other health care customers to diagnose, treat, and monitor intestinal diseases and other medical conditions. Prior to this sale, we accounted for this interest in TechLab as an equity method investment. Alere served as a distributor of TechLab products prior to the September 16, 2016 sale and will remain the principal global distributor of TechLab products pursuant to the terms of a distribution agreement with TechLab. We made product purchases from TechLab of $4.6 million during the three months ended March 31, 2016.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(15) Commitments and Contingencies (a) Acquisition-related Contingent Consideration Obligations We have contractual contingent purchase price consideration obligations related to certain of our acquisitions. We determine the acquisition date fair value of the contingent consideration obligations based on a probability-weighted approach derived from the overall likelihood of achieving certain performance targets, including product development milestones or financial metrics. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement, as defined in fair value measurement accounting. The resultant probability-weighted earn-out Increases or decreases in the fair values of the contingent consideration obligations may result from, among other things, changes in discount periods and rates, changes in the timing and amount of earn-out earn-out The following table summarizes our contractual contingent purchase price consideration obligations related to certain of our acquisitions (in thousands): Acquisition Acquisition Date Acquisition Date Fair Value Maximum Remaining Earn-out Potential as of March 31, 2017 Remaining Earn-out Period as of March 31, 2017 Estimated Fair Value as of March 31, 2017 Estimated Fair Value as of December 31, 2016 Payments Made During 2017 TwistDx, Inc. (1) March 11, 2010 $ 35,600 $ 102,535 2017 – 2025 (3) $ 36,300 $ 35,700 $ 159 Epocal (2) February 1, 2013 $ 75,000 $ 15,375 2017 – 2018 3,000 3,000 — Other Various $ 30,373 $ — 4,100 4,500 128 $ 43,400 $ 43,200 $ 287 (1) The terms of the acquisition agreement require us to pay earn-outs upon successfully meeting certain revenue and product development targets through 2025. (2) The terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. (3) The maximum earn-out (b) Legal Proceedings Litigation with Abbott Laboratories After entering into the original Merger Agreement, Abbott informed Alere that it had serious concerns about, among other things, the accuracy of various representations, warranties and covenants made by Alere in the original Merger Agreement. Abbott indicated that these concerns related to the delay in the filing of Alere’s Annual Report on Form 10-K On August 25, 2016, Alere filed a complaint against Abbott in the Delaware Chancery Court, and filed an accompanying motion to expedite the proceedings, asking the Delaware Chancery Court to require Abbott to specifically perform its obligations with respect to obtaining antitrust approvals as required by the original Merger Agreement. On September 29, 2016, the Delaware Chancery Court entered an order that, among other things, adopted a detailed schedule setting forth actions required to be taken by specified dates in order to obtain all antitrust clearances required by the original merger agreement. On November 3, 2016, Abbott filed a complaint against Alere in the Delaware Chancery Court asserting a claim against Alere for breach of contract from Alere’s alleged refusal to provide Abbott with certain information under the original Merger Agreement. On February 1, 2017, Alere filed a motion to dismiss Abbott’s November 3 complaint. On December 7, 2016, Abbott filed a complaint (which was subsequently amended after the various actions were consolidated) in the Delaware Chancery Court seeking a declaration that Alere had experienced a Material Adverse Effect (as such term is defined in the original Merger Agreement) and that Abbott could terminate the original Merger Agreement. On February 1, 2017, Abbott filed its answer to the complaint Alere had filed on August 25, 2016, and Alere filed an answer to Abbott’s amended complaint as well as counterclaims against Abbott. Alere’s counterclaims requested a declaratory judgment that, among other things, (i) there had been no Material Adverse Effect (as such term is defined in the original Merger Agreement); and (ii) Abbott had breached the parties’ original Merger Agreement and breached the implied covenant of good faith and fair dealing. Settlement Agreement relating to the Amended Merger Agreement Concurrently with the execution of the Merger Agreement Amendment on April 13, 2017, Alere and Abbott entered into a settlement agreement, or the Settlement Agreement. The Settlement Agreement released claims arising out of or related to the merger, and resolved the parties’ litigation that had been pending in Delaware Chancery Court. The Settlement Agreement provided reciprocal releases, except for any potential antitrust claims by Alere to the extent they relate to developments after August 25, 2016, which would not be released until the parties obtain all consents and regulatory clearances necessary for closing. Abbott’s potential claims based on information not excluded from the definition of Material Adverse Effect in the Amended Merger Agreement were also not released. Finally, the Settlement Agreement provided for dismissal of the Delaware litigation with prejudice, with the exception of the non-released Arriva Medical Billing Number Arriva Medical is our durable medical equipment, or DME, supply business that furnishes diabetic testing supplies via mail order, including blood glucose monitors, test strips, lancets, lancing devices, and control solutions, as well as other related medical supplies in the United States. These products are generally covered by Medicare, Medicaid and other third-party payers. Competition for Medicare-reimbursed diabetes testing supplies, which represents the majority of our Arriva Medical business, changed significantly in 2013 as a result of implementation by CMS of a competitive bidding process to limit the number of eligible suppliers and the fees for which they may be reimbursed. Based on the most recent bidding process, we estimate that CMS currently reimburses approximately ten suppliers who have agreed to accept a contractual reimbursement rate for mail-order diabetic testing supplies for the period from July 2016 to December 2018 that is substantially lower than the established fee schedule for these products. Arriva Medical is one of those approximately ten suppliers that was awarded a national mail-order contract. Suppliers that were not awarded contracts are unable to be reimbursed by Medicare for mail-order diabetic testing supplies. On October 12, 2016, Arriva Medical received a notice, dated October 5, 2016, that its Medicare enrollment would be revoked by CMS, based on CMS’ assertion that, over a five-year period, out of approximately 5.7 million Medicare claims made for about one million unique beneficiaries, Arriva had allegedly submitted claims for 211 Medicare beneficiaries who were deceased on the date their products were shipped (even if the products were appropriately ordered in advance of the patient’s death). Arriva Medical’s initial appeal of this determination was denied by CMS, and Arriva’s Medicare enrollment was revoked effective November 4, 2016, pending the outcome of further appeals. Arriva Medical conducted an investigation into the issue and does not believe that it received or, if received, retained, any Medicare reimbursement for the DME items at issue for these 211 Medicare beneficiaries. In addition, CMS subsequently provided notice that Arriva Medical’s competitive bidding contract would be terminated as a result of the revocation of its enrollment. On December 27, 2016, Arriva Medical filed an appeal for an administrative law judge, or ALJ, hearing seeking to permanently reinstate Arriva’s Medicare enrollment status retroactive to the November 4, 2016 revocation date. On April 25, 2017, the ALJ upheld CMS’s revocation of Arriva Medical’s Medicare enrollment. On June 7, 2017, Arriva Medical has timely appealed the ALJ decision to the Department Appeals Board. On December 28, 2016, Arriva Medical also filed a complaint in Federal District Court for the District of Columbia requesting a temporary restraining order, or TRO, and preliminary injunction, or PI, to prohibit CMS from terminating Arriva Medical’s competitive bidding contract and requesting that the court require CMS to reinstate Arriva’s Medicare billing status until due process could be provided in the form of the completion of the administrative appeals process prescribed by regulation. In conjunction with this case, on January 4, 2017, CMS agreed through its counsel that it would not revoke the competitive bidding contract while the administrative appeals process was underway, which mooted the request for the TRO. On March 9, 2017, the Federal District Court for the District of Columbia denied the PI to prohibit CMS from terminating Arriva Medical’s competitive bidding contract and also denied CMS’s motion to dismiss Arriva Medical’s complaint. On April 17, 2017, the court issued an order dismissing Arriva Medical’s complaint. We are unable, at this time, to determine the outcome of these pending legal matters related to Arriva Medical’s billing number. U.S. Securities and Exchange Commission Subpoena On August 28, 2015, we received a subpoena from the SEC which indicated that it is conducting a formal investigation of Alere. The SEC’s subpoena relates to, among other things, (i) our previously filed restatement and revision to our financial statements, including the accounting for deferred taxes for discontinued operations, as well as our tax strategies and policies and (ii) our sales practices and dealings with third parties (including distributors and foreign government officials) in Africa relating to sales to government entities. On January 14, 2016, we received a second subpoena from the SEC in connection with this formal investigation seeking, among other things, additional information related to sales of products and services to end-users end-users Form 10-K We are cooperating with the SEC and have provided documents in response to the subpoenas and voluntary requests and we have made witnesses available to be interviewed by the SEC. We are unable to predict when this matter will be resolved or what further action, if any, the SEC may take in connection with it. Department of Justice Grand Jury Subpoena On March 11, 2016, we received a grand jury subpoena from the United States Department of Justice requiring the production of documents relating to, among other things, sales, sales practices and dealings with third parties (including distributors and foreign governmental officials) in Africa, Asia and Latin America and other matters related to the U.S. Foreign Corrupt Practices Act. We are cooperating with the Department of Justice and have provided information in response to the subpoena. We are unable to predict when this matter will be resolved or what further action, if any, the Department of Justice may take in connection with it. Securities Class Actions On April 21, 2016 and May 4, 2016 two class action lawsuits captioned Godinez Alere Inc. Breton Alere Inc. and Rule 10b-5 under On November 14, 2016, a class action lawsuit captioned Khalid Alere Inc. 10b-5 We are unable at this time to determine the outcome of these class action lawsuits or our potential liability, if any. Matters Relating to our San Diego Facility On October 9, 2012, we received a warning letter from the FDA referencing inspectional observations set forth in a Form FDA 483 received in June 2012. The observations were the result of an inspection of our San Diego facility conducted earlier during 2012 relating to our Alere Triage products, which resulted in two recalls of certain Alere Triage products and revised release specifications for our Alere Triage meter-based products. In September 2014, as follow up to a further inspection of our San Diego facility, the FDA notified us that this inspection was classified “voluntary action indicated,” meaning that the objectionable conditions or practices found in the inspection did not meet the threshold of significance requiring regulatory action, but that formal close-out In May 2012, we also received a subpoena from the Office of Inspector General of the Department of Health and Human Services, or the OIG, seeking documents relating primarily to the quality control testing and performance characteristics of Alere Triage products. We are cooperating with the government and are responding to the investigation, which is ongoing. We have been engaged in discussions with the government about this matter, including a resolution of potential related False Claims Act and common law liability exposure for the products under review. As a result of these discussions, management accrued, as of December 31, 2016, an aggregate of $35.0 million for potential liability of the claims related to this matter. We would need to obtain certain approvals before we could agree to any proposed resolution. There can be no assurance that future discussions with the government to resolve these matters will be successful, that the approvals we need will be obtained or that any potential settlement will be agreed to or finalized. We are unable to predict when these matters will be resolved or what further action, if any, the government will take in connection with them. Based on the ongoing uncertainties and potentially wide range of outcomes associated with any potential resolution of the matter under investigation by the OIG, the ultimate amount of potential liability may materially exceed the $35.0 million accrual we have established. INRatio Class Actions On May 26, 2016, a class action lawsuit captioned Dina Andren Sidney Bludman v. Alere Inc., et al. We are unable, at this time, to determine the outcome of these class action lawsuits or our potential liability, if any. Another class action lawsuit captioned J.E, J.D., and all others similarly situated v. Alere Inc., Alere San Diego, Inc. and Alere Home Monitoring, Inc., Claims in the Ordinary Course and Other Matters We are also party to certain other legal proceedings and other governmental investigations, or are requested to provide information in connection with such proceedings or investigations. For example, in December 2014, we and our subsidiary, Avee Laboratories Inc., or Avee, received subpoenas from the United States Attorney for the District of New Jersey seeking marketing materials and other documents relating primarily to billing and marketing practices related to toxicology testing. We are cooperating with this investigation and are providing documents in response to the subpoena. We and our subsidiary, Arriva Medical, LLC, are also in the process of responding to Civil Investigative Demands, or CIDs, from the United States Attorney’s office for the Middle District of Tennessee and the U.S. Department of Justice in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The most recent of the CIDs related to this matter was received in May 2017. The CIDs request patient and insurance billing and medical records, records related to interactions with third parties, and correspondence related to the same, communications with customers and terms of sale for diabetic products, dating back to January 2010. In an unrelated matter, in January 2017, our subsidiary Alere Home Monitoring, Inc., which offers home self-testing anticoagulation monitoring and VAD services and products, received a CID from the United States Attorney’s Office for the District of Massachusetts. The January 2017 CID, which covers similar subject matter to a letter request from the Department of Justice Civil Division dating back to June 2015, is broad in scope, but is understood to be primarily focused on obtaining records and information about Alere Home Monitoring, Inc.’s billing practices and policies relating to the frequency at which PT/INR self-testing is prescribed and performed since 2006. In addition, in March 2017, Alere Home Monitoring, Inc. received a second letter request from the Department of Justice Civil Division seeking additional information regarding billing frequencies of PT/INR self-testing beyond the original scope of the June 2015 request. We are cooperating with these various unrelated investigations and are providing documents and information responsive to each of the CIDs and letter requests. We cannot predict what effect, if any, these investigations, or any resulting claims, could have on us or our subsidiaries. As previously disclosed, we received a U.S. Department of Justice criminal subpoena addressed to Alere Toxicology Services, Inc. on July 1, 2016 which seeks records related to Medicare, Medicaid and Tricare billings dating back to 2010 for specific patient samples tested at our Austin, Texas pain management laboratory and payments made to physicians. On June 8, 2017 we were informed that the U.S. Department of Justice is closing this investigation without taking any action against the Company or Alere Toxicology Services, Inc. We have received, from time to time, additional subpoenas and requests for information from the United States Department of Justice, other federal government agencies and state attorneys general, and we have, in each of these cases, cooperated with the applicable governmental entity in responding to the applicable subpoena or request for information. For example, in May 2016, we received a subpoena from the U.S. Attorney for the District of New Jersey, which seeks various documents related to the accuracy, reliability and performance of the INRatio system, including documents relating to prior interactions with the FDA and others regarding the system. Our diabetes, toxicology and patient self-testing businesses are subject to audit and claims for reimbursement brought in the ordinary course by: private third-party payers, including health insurers; Zone Program Integrity Contractors, or ZPICs; and Medicare Administrative Contractors, or MACs, to monitor compliance with coverage and reimbursement rules and guidelines. These types of audits and claims can include, but are not limited to, claims relating to proper documentation and support, claims relating to the medical necessity of certain testing or billing practices are not in accord with applicable rules and guidelines and can lead to assertions or determinations that certain claims should not have been, or will no longer be, paid by the private third-party payer or by Medicare or Medicaid. In such cases, the payer or program may seek to recoup or offset amounts they assert have been paid in error. Our businesses may also be subject at any time to other commercial disputes, product liability claims, personal injury claims, including claims arising from or relating to product recalls, negligence claims, third-party subpoenas or various other lawsuits arising in the ordinary course of business, including infringement, employment or investor matters, disputes regarding the payment of contingent consideration obligations and we expect that this will continue to be the case in the future. For example, several individuals have filed suits against us alleging personal injury claims in connection with the use of our INRatio products (which are in addition to the class action suits described above). In addition, the former shareholders of Ionian Technologies Inc. filed a lawsuit against us in May 2017 alleging, among other things, that they are owed $30.0 million in earn-out Such lawsuits or claims generally seek damages or reimbursement, sometimes in substantial amounts. There are possible unfavorable outcomes related to litigation or governmental investigations that could materially impact our business, results of operations, financial condition, and cash flows.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2017
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	(16) Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that we adopt on or before the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position, results of operations, comprehensive income or cash flows upon adoption. Please also see Note 5(w), Recent Accounting Pronouncements 10-K Recently Issued Standards In March 2017, the FASB issued ASU No. 2017-07, 2017-07. 2017-07 2017-07 2017-07 In January 2017, the FASB issued ASU No. 2017-04, Intangibles — Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment 2017-04. 2017-04 2017-04 2017-04 In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business 2017-01. 2017-01 2017-01 ASU 2017-01 In December 2016, the FASB issued ASU No. 2016-20, Technical Corrections and Improvements to Topic 606: Revenue from Contracts with Customers 2016-20. 2016-20 2014-09, 2016-20 2016-20 In December 2016, the FASB issued ASU No. 2016-19, Technical Corrections and Improvements 2016-19. 2016-19 2016-19 2016-19 In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, ASU 2016-18. 2016-18 beginning-of-period end-of-period 2016-18 ASU 2016-18 In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, 2016-16. 2016-16 2016-16 2016-16 In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, 2016-15. 2016-15 zero-coupon 2016-15 ASU 2016-15 In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, 2016-12. 2016-12: 606-10-25-7; non-cash 2016-12 2016-12 In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, 2016-10. 2016-10 2016-10 2016-10 In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), 2016-02. 2016-02 right-of-use 2016-02 ASU 2016-02 In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers 2014-09, 2014-09 one-year 2014-09 We believe that there were no other accounting standards recently issued that had or are expected to have a material impact on our consolidated financial statements. Recently Adopted Standards In March 2016, the FASB issued ASU No. 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting 2016-09. 2016-09 2016-09 2016-09. 2016-09 • All excess tax benefits or tax deficiencies are now recognized as income tax benefit or expense as applicable. Previously, we recorded the benefit or expense to additional paid-in • All cash payments made to taxing authorities on the employees’ behalf for withheld shares are now presented as financing activities on the statement of cash flows. Previously, it was required to be classified within operating activities. This change was applied retrospectively with a reclassification of $1.4 million from operating to financing activities during the three months ended March 31, 2016. We have elected to continue to estimate forfeitures expected to occur to determine the amount of compensation cost to be recognized in each period. None of the other provisions in this guidance had a significant impact on our consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-07, Investments — Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting, 2016-07. 2016-07 step-by-step 2016-07 2016-07 available-for-sale 2016-07 2016-07. 2016-07 In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, ASU 2015-11. 2015-11 in-scope ASU 2015-11 2015-11 2015-11. 2015-11

Equity Investments

Equity Investments	3 Months Ended
	Mar. 31, 2017
Equity Method Investments and Joint Ventures [Abstract]
Equity Investments	(17) Equity Investments We account for the results from our equity investments under the equity method of accounting in accordance with ASC 323, Investments—Equity Method and Joint Ventures, (a) SPD We recorded earnings of $5.0 million and $4.6 million during the three months ended March 31, 2017 and 2016, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying consolidated statements of operations, which represented our 50% share of SPD’s net income for the respective periods and elimination of intercompany profit in inventory related to sales from Alere to SPD which is reflected in SPD’s net income. (b) TechLab We recorded earnings of $0.2 million and $0.5 million during the three months ended March 31, 2017 and 2016, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying consolidated statements of operations, which represented our minority share of TechLab’s net income for the respective periods. On September 16, 2016, we completed the sale of our 49% interest in the TechLab business and, in connection with such sale, we recorded a gain in equity earnings of unconsolidated entities of $29.9 million. Summarized financial information for SPD (and TechLab on a combined basis for the three months ended March 31, 2016) is as follows (in thousands): Three Months Ended March 31, Combined Condensed Results of Operations: 2017 2016 Net revenue $ 45,392 $ 53,434 Gross profit $ 35,133 $ 36,219 Net income after taxes $ 10,048 $ 10,141 Combined Condensed Balance Sheet: March 31, 2017 December 31, 2016 Current assets $ 85,888 $ 75,248 Non-current 21,246 20,578 Total assets $ 107,134 $ 95,826 Current liabilities $ 43,890 $ 44,234 Non-current 3,945 3,875 Total liabilities $ 47,835 $ 48,109 The dividends we received in cash as a return from capital from our equity investments have been included in cash flows from investing activities in our consolidated statements of cash flows for all the periods presented.

Impairment and (Gain) Loss on D

Impairment and (Gain) Loss on Dispositions, Net	3 Months Ended
	Mar. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Impairment and (Gain) Loss on Dispositions, Net	(18) Impairment and (Gain) Loss on Dispositions, Net In January 2016, we completed the sale of our Alere E-Santé E-Santé The financial results for the above business are immaterial to our consolidated financial results.

Provision (Benefit) for Income

Provision (Benefit) for Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Provision (Benefit) for Income Taxes	(19) Provision (Benefit) for Income Taxes The provision for income taxes increased by $18.8 million to $18.6 million for the three months ended March 31, 2017, from a benefit of $0.2 million for the three months ended March 31, 2016. The effective tax rate for the three months ended March 31, 2017 and 2016, was (37%) and 2%, respectively. The Company determines its estimated annual effective tax rate at the end of each interim period based on forecasted pre-tax income (loss) and facts known at that time. The estimated annual effective tax rate is applied to the year-to-date pre-tax income (loss) at the end of each interim period with certain adjustments. The tax effect of significant unusual or extraordinary items is discretely reflected in the period in which they occur. Our estimated annual effective tax rate is calculated based on forecasted pre-tax income (loss) across various jurisdictions, and can change based on the mix of jurisdictional pre-tax income (loss) and other factors. Our $0.2 million income tax benefit for the three months ended March 31, 2016 is primarily related to foreign incomes taxes based on forecasted and year-to-date pre-tax foreign income (loss) by jurisdiction offset by U.S. federal and state income tax benefits based on forecasted and year-to-date pre-tax U.S. federal and state income (loss). Our $18.6 million income tax provision for the three months ended March 31, 2017 is primarily related to foreign incomes taxes based on forecasted and year-to-date pre-tax foreign income by jurisdiction as well as U.S. federal and state income taxes in connection with the increase of deferred tax liabilities on indefinite-lived intangible assets and certain other state income taxes. As of December 31, 2016, we recorded a valuation allowance due to uncertainties related to the future benefits and realization of our deferred tax assets related to U.S. federal and state net deferred tax assets and as such no U.S. federal and state income tax benefits were recorded related to the pre-tax U.S. federal and state loss during the three months ended March 31, 2017.

Guarantor Financial Information

Guarantor Financial Information	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Guarantor Financial Information	(20) Guarantor Financial Information Our 7.25% senior notes, our 6.5% senior subordinated notes and our 6.375% senior subordinated notes are guaranteed by certain of our consolidated 100% owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, balance sheets as of March 31, 2017 and December 31, 2016, the related statements of operations, statements of comprehensive income (loss) and statements of cash flows for the three months ended March 31, 2017 and 2016, respectively, for Alere Inc., the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Non-Guarantor We have extensive transactions and relationships between various members of the consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost-sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties. For comparative purposes, certain amounts for prior periods have been reclassified to conform to the current period classification. Prior periods have been presented on a basis that is consistent with the current period, giving retrospective effect to the impact of discontinued operations. The quantitative impacts of the Restatement on the guarantor financial information are included in Note 29 to the consolidated financial statements in the Annual Report on Form 10-K CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended March 31, 2017 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 263,294 $ 272,910 $ (72,759 ) $ 463,445 Services revenue — 109,531 12,598 — 122,129 Net product sales and services revenue — 372,825 285,508 (72,759 ) 585,574 License and royalty revenue — 3,730 854 (1,942 ) 2,642 Net revenue — 376,555 286,362 (74,701 ) 588,216 Cost of net product sales 1,139 131,757 161,862 (64,927 ) 229,831 Cost of services revenue 45 76,484 7,588 (8,218 ) 75,899 Cost of net product sales and services revenue 1,184 208,241 169,450 (73,145 ) 305,730 Cost of license and royalty revenue — — 2,702 (1,942 ) 760 Cost of net revenue 1,184 208,241 172,152 (75,087 ) 306,490 Gross profit (loss) (1,184 ) 168,314 114,210 386 281,726 Operating expenses: Research and development 1,220 17,890 7,174 — 26,284 Sales and marketing 1,925 48,344 43,922 — 94,191 General and administrative 94,300 34,522 37,764 (313 ) 166,273 Impairment and (gain) loss on dispositions, net — — — — — Operating income (loss) (98,629 ) 67,558 25,350 699 (5,022 ) Interest expense, including amortization of original issue discounts and deferred financing costs (42,961 ) (1,877 ) (2,278 ) 3,933 (43,183 ) Other income (expense), net 2,577 1,552 (2,711 ) (3,934 ) (2,516 ) Income (loss) before provision for income taxes (139,013 ) 67,233 20,361 698 (50,721 ) Provision for income taxes 13,547 — 5,062 — 18,609 Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax (152,560 ) 67,233 15,299 698 (69,330 ) Equity in earnings of subsidiaries, net of tax 88,202 — — (88,202 ) — Equity earnings of unconsolidated entities, net of tax 229 — 4,972 — 5,201 Net income (loss) (64,129 ) 67,233 20,271 (87,504 ) (64,129 ) Less: Net income attributable to non-controlling — — 183 — 183 Net income (loss) attributable to Alere Inc. and Subsidiaries (64,129 ) 67,233 20,088 (87,504 ) (64,312 ) Preferred stock dividends (5,250 ) — — — (5,250 ) Net income (loss) available to common stockholders $ (69,379 ) $ 67,233 $ 20,088 $ (87,504 ) $ (69,562 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended March 31, 2016 (As Restated) (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 224,380 $ 305,568 $ (61,446 ) $ 468,502 Services revenue — 104,484 11,225 — 115,709 Net product sales and services revenue — 328,864 316,793 (61,446 ) 584,211 License and royalty revenue — 2,920 2,558 (2,749 ) 2,729 Net revenue — 331,784 319,351 (64,195 ) 586,940 Cost of net product sales 114 124,758 169,845 (53,393 ) 241,324 Cost of services revenue — 72,495 8,040 (7,435 ) 73,100 Cost of net product sales and services revenue 114 197,253 177,885 (60,828 ) 314,424 Cost of license and royalty revenue — 17 4,123 (2,749 ) 1,391 Cost of net revenue 114 197,270 182,008 (63,577 ) 315,815 Gross profit (loss) (114 ) 134,514 137,343 (618 ) 271,125 Operating expenses: Research and development 4,134 14,459 8,469 — 27,062 Sales and marketing 1,336 54,465 44,839 — 100,640 General and administrative 44,615 33,186 37,155 — 114,956 Impairment and (gain) loss on dispositions, net — — (3,810 ) — (3,810 ) Operating income (loss) (50,199 ) 32,404 50,690 (618 ) 32,277 Interest expense, including amortization of original issue discounts and deferred financing costs (41,087 ) (2,652 ) (3,067 ) 4,700 (42,106 ) Other income (expense), net 1,988 2,502 (1,139 ) (4,700 ) (1,349 ) Income (loss) before provision (benefit) for income taxes (89,298 ) 32,254 46,484 (618 ) (11,178 ) Provision (benefit) for income taxes (54 ) 250 (368 ) — (172 ) Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax (89,244 ) 32,004 46,852 (618 ) (11,006 ) Equity in earnings of subsidiaries, net of tax 82,591 — — (82,591 ) — Equity earnings of unconsolidated entities, net of tax 681 — 4,581 (228 ) 5,034 Net income (loss) (5,972 ) 32,004 51,433 (83,437 ) (5,972 ) Less: Net income attributable to non-controlling — — 103 — 103 Net income (loss) attributable to Alere Inc. and Subsidiaries (5,972 ) 32,004 51,330 (83,437 ) (6,075 ) Preferred stock dividends (5,309 ) — — — (5,309 ) Net income (loss) available to common stockholders $ (11,281 ) $ 32,004 $ 51,330 $ (83,437 ) $ (11,384 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended March 31, 2017 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ (64,129 ) $ 67,233 $ 20,271 $ (87,504 ) $ (64,129 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 27 164 53,180 (41 ) 53,330 Minimum pension liability adjustment — — (71 ) — (71 ) Other comprehensive income, before tax 27 164 53,109 (41 ) 53,259 Other comprehensive income 27 164 53,109 (41 ) 53,259 Comprehensive income (loss) (64,102 ) 67,397 73,380 (87,545 ) (10,870 ) Less: Comprehensive income attributable to non-controlling — — 183 — 183 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (64,102 ) $ 67,397 $ 73,197 $ (87,545 ) $ (11,053 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended March 31, 2016 (As Restated) (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ (5,972 ) $ 32,004 $ 51,433 $ (83,437 ) $ (5,972 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 115 (129 ) 22,207 — 22,193 Minimum pension liability adjustment — — 155 — 155 Other comprehensive income (loss), before tax 115 (129 ) 22,362 — 22,348 Other comprehensive income (loss) 115 (129 ) 22,362 — 22,348 Comprehensive income (loss) (5,857 ) 31,875 73,795 (83,437 ) 16,376 Less: Comprehensive income attributable to non-controlling — — 103 — 103 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (5,857 ) $ 31,875 $ 73,692 $ (83,437 ) $ 16,273 CONSOLIDATING BALANCE SHEET March 31, 2017 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 215,718 $ 4,168 $ 381,586 $ — $ 601,472 Restricted cash 814 — 52,329 — 53,143 Marketable securities — 83 457 — 540 Accounts receivable, net of allowances — 182,775 204,912 — 387,687 Inventories, net — 162,740 183,813 (24,080 ) 322,473 Prepaid expenses and other current assets 21,817 23,570 67,839 4,602 117,828 Intercompany receivables 383,305 1,106,663 110,136 (1,600,104 ) — Total current assets 621,654 1,479,999 1,001,072 (1,619,582 ) 1,483,143 Property, plant and equipment, net 23,061 241,058 180,798 (5,115 ) 439,802 Goodwill — 1,823,446 957,654 — 2,781,100 Other intangible assets with indefinite lives — 7,472 14,705 (59 ) 22,118 Finite-lived intangible assets, net 2,362 487,478 298,425 (3,200 ) 785,065 Restricted cash — — 2,355 — 2,355 Other non-current 463 1,739 12,946 (808 ) 14,340 Investments in subsidiaries 3,554,484 158,631 57,651 (3,770,766 ) — Investments in unconsolidated entities 875 14,765 47,932 15,655 79,227 Deferred tax assets — — 59,811 (37,336 ) 22,475 Non-current 4,580 — 39,664 — 44,244 Intercompany notes receivables 1,677,641 633,767 3,000 (2,314,408 ) — Total assets $ 5,885,120 $ 4,848,355 $ 2,676,013 $ (7,735,619 ) $ 5,673,869 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 40,073 $ 4 $ 42,429 $ — $ 82,506 Current portion of capital lease obligations — 1,433 1,468 — 2,901 Accounts payable 56,545 77,416 77,469 — 211,430 Accrued expenses and other current liabilities 146,351 133,109 171,964 (34,977 ) 416,447 Intercompany payables 505,213 860,907 233,912 (1,600,032 ) — Total current liabilities 748,182 1,072,869 527,242 (1,635,009 ) 713,284 Long-term liabilities: Long-term debt, net of current portion 2,847,092 — 5,234 — 2,852,326 Capital lease obligations, net of current portion — 1,732 4,942 — 6,674 Deferred tax liabilities — 61,928 58,817 81 120,826 Other long-term liabilities 94,324 44,941 21,679 (808 ) 160,136 Intercompany notes payables 379,701 1,188,611 746,096 (2,314,408 ) — Total long-term liabilities 3,321,117 1,297,212 836,768 (2,315,135 ) 3,139,962 Total stockholders’ equity 1,815,821 2,478,274 1,307,201 (3,785,475 ) 1,815,821 Non-controlling — — 4,802 — 4,802 Total equity 1,815,821 2,478,274 1,312,003 (3,785,475 ) 1,820,623 Total liabilities and equity $ 5,885,120 $ 4,848,355 $ 2,676,013 $ (7,735,619 ) $ 5,673,869 CONSOLIDATING BALANCE SHEET December 31, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 167,639 $ 3,161 $ 396,415 $ — $ 567,215 Restricted cash 1,337 — 50,213 — 51,550 Marketable securities — 76 — — 76 Accounts receivable, net of allowances — 186,067 227,468 — 413,535 Inventories, net — 168,736 163,967 (23,783 ) 308,920 Prepaid expenses and other current assets 15,983 22,318 68,748 11,558 118,607 Intercompany receivables 390,328 1,008,767 204,587 (1,603,682 ) — Total current assets 575,287 1,389,125 1,111,398 (1,615,907 ) 1,459,903 Property, plant and equipment, net 25,525 243,755 176,618 (4,708 ) 441,190 Goodwill — 1,822,290 937,076 — 2,759,366 Other intangible assets with indefinite lives — 7,457 19,765 (58 ) 27,164 Finite-lived intangible assets, net 2,490 507,060 299,227 (3,200 ) 805,577 Restricted cash — — 2,171 — 2,171 Other non-current 509 2,267 13,060 (870 ) 14,966 Investments in subsidiaries 3,409,001 158,195 57,650 (3,624,846 ) — Investments in unconsolidated entities 684 14,765 42,523 14,253 72,225 Deferred tax assets — — 57,819 (37,336 ) 20,483 Non-current 4,580 — 40,654 — 45,234 Intercompany notes receivables 1,757,723 709,965 744 (2,468,432 ) — Total assets $ 5,775,799 $ 4,854,879 $ 2,758,705 $ (7,741,104 ) $ 5,648,279 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 40,072 $ — $ 42,298 $ — $ 82,370 Current portion of capital lease obligations — 1,560 1,504 — 3,064 Accounts payable 35,591 78,981 81,307 — 195,879 Accrued expenses and other current liabilities 65,582 133,506 223,778 (28,023 ) 394,843 Intercompany payables 485,573 859,924 258,154 (1,603,651 ) — Total current liabilities 626,818 1,073,971 607,041 (1,631,674 ) 676,156 Long-term liabilities: Long-term debt, net of current portion 2,852,978 — 5,227 — 2,858,205 Capital lease obligations, net of current portion — 2,029 5,192 — 7,221 Deferred tax liabilities — 51,314 67,702 82 119,098 Other long-term liabilities 91,042 44,563 21,257 (870 ) 155,992 Intercompany notes payables 377,969 1,274,419 816,044 (2,468,432 ) — Total long-term liabilities 3,321,989 1,372,325 915,422 (2,469,220 ) 3,140,516 Total stockholders’ equity 1,826,992 2,408,583 1,231,627 (3,640,210 ) 1,826,992 Non-controlling — — 4,615 — 4,615 Total equity 1,826,992 2,408,583 1,236,242 (3,640,210 ) 1,831,607 Total liabilities and equity $ 5,775,799 $ 4,854,879 $ 2,758,705 $ (7,741,104 ) $ 5,648,279 CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2017 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (64,129 ) $ 67,233 $ 20,271 $ (87,504 ) $ (64,129 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (88,202 ) — — 88,202 — Non-cash 4,251 1 29 — 4,281 Depreciation and amortization 2,390 37,398 21,384 (238 ) 60,934 Non-cash 6,241 1,857 2,265 — 10,363 Impairment of long-lived assets — (342 ) — — (342 ) Loss on sales of fixed assets — 2,222 119 — 2,341 Equity earnings of unconsolidated entities, net of tax (229 ) — (4,972 ) — (5,201 ) Deferred income taxes 2,252 — (5,629 ) — (3,377 ) Other non-cash 286 102 1,172 4 1,564 Non-cash — 759 (270 ) — 489 Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — 3,815 29,290 — 33,105 Inventories, net — (3,207 ) (15,605 ) (460 ) (19,272 ) Prepaid expenses and other current assets (5,982 ) (1,409 ) 4,186 6,955 3,750 Accounts payable 21,415 (1,170 ) (6,882 ) — 13,363 Accrued expenses and other current liabilities 78,365 494 (54,191 ) (6,954 ) 17,714 Other non-current 921 9,665 (4,934 ) — 5,652 Cash paid for contingent consideration — (159 ) — — (159 ) Intercompany payable (receivable) 111,553 (109,644 ) (2,158 ) 249 — Net cash provided by (used in) operating activities 69,132 7,615 (15,925 ) 254 61,076 Cash Flows from Investing Activities: (Increase) decrease in restricted cash 523 — (1,968 ) — (1,445 ) Purchases of property, plant and equipment (624 ) (5,143 ) (4,942 ) 310 (10,399 ) Proceeds from sale of property, plant and equipment — 3 446 (310 ) 139 Cash paid for business acquisitions, net of cash acquired (3,100 ) 40 — — (3,060 ) Cash received from sales of marketable securities — (7 ) — — (7 ) Cash paid for equity investments (191 ) — (41 ) — (232 ) Proceeds from sale of equity investments 229 — — — 229 Decrease in other assets 47 4 31 — 82 Net cash provided by (used in) investing activities (3,116 ) (5,103 ) (6,474 ) — (14,693 ) Cash Flows from Financing Activities: Cash paid for contingent consideration — — (128 ) — (128 ) Proceeds from issuance of common stock, net of issuance costs 496 — — — 496 Payments on long-term debt (10,018 ) — (140 ) — (10,158 ) Net proceeds (payments) under revolving credit facilities — — 48 — 48 Cash paid for dividends (5,323 ) — — — (5,323 ) Cash paid for employee taxes related to shares withheld (3,092 ) (1,095 ) (1,414 ) — (5,601 ) Principal payments on capital lease obligations — (424 ) (428 ) — (852 ) Net cash used in financing activities (17,937 ) (1,519 ) (2,062 ) — (21,518 ) Foreign exchange effect on cash and cash equivalents — 14 9,632 (254 ) 9,392 Net increase (decrease) in cash and cash equivalents 48,079 1,007 (14,829 ) — 34,257 Cash and cash equivalents, beginning of period 167,639 3,161 396,415 — 567,215 Cash and cash equivalents, end of period $ 215,718 $ 4,168 $ 381,586 $ — $ 601,472 CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2016 (As Restated) (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (5,972 ) $ 32,004 $ 51,433 $ (83,437 ) $ (5,972 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (82,591 ) — — 82,591 — Non-cash 2,188 4 44 — 2,236 Depreciation and amortization 2,203 45,691 23,722 888 72,504 Non-cash 5,069 2,287 2,246 — 9,602 Impairment of inventory — — 1,349 — 1,349 Impairment of long-lived assets — 608 — — 608 Loss on sale of fixed assets 15 8 300 — 323 Equity earnings of unconsolidated entities, net of tax (681 ) — (4,581 ) 228 (5,034 ) Deferred income taxes — (100 ) (6,712 ) — (6,812 ) Gain on business dispositions — — (3,810 ) — (3,810 ) Other non-cash 105 303 2,088 — 2,496 Non-cash (1,000 ) 1,199 (57 ) — 142 Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — (7,875 ) (10,055 ) — (17,930 ) Inventories, net — (6,681 ) (3,333 ) (270 ) (10,284 ) Prepaid expenses and other current assets (1,137 ) 1,514 (6,177 ) 25 (5,775 ) Accounts payable (3,694 ) (6,773 ) (21,075 ) — (31,542 ) Accrued expenses and other current liabilities 10,584 (94,355 ) 78,614 (25 ) (5,182 ) Other non-current 157,791 (159,277 ) 1,583 (62 ) 35 Cash paid for contingent consideration (143 ) — — — (143 ) Intercompany payable (receivable) (111,564 ) 180,953 (69,389 ) — — Net cash provided by (used in) operating activities (28,827 ) (10,490 ) 36,190 (62 ) (3,189 ) Cash Flows from Investing Activities: (Increase) decrease in restricted cash (513 ) — 77 — (436 ) Purchases of property, plant and equipment (841 ) (5,615 ) (8,048 ) — (14,504 ) Proceeds from sale of property, plant and equipment — 40 572 — 612 Cash received from (used in) business dispositions, net of cash divested (1,337 ) — 22,807 — 21,470 Cash paid for business acquisitions, net of cash acquired — — (5,945 ) — (5,945 ) Cash received from sales of marketable securities — 93 — — 93 Cash received from equity method investments 2,205 — — — 2,205 Cash paid for equity investments (184 ) — — — (184 ) Increase in other assets (64 ) (98 ) (440 ) 62 (540 ) Net cash provided by (used in) investing activities (734 ) (5,580 ) 9,023 62 2,771 Cash Flows from Financing Activities: Cash paid for financing costs (1 ) — — — (1 ) Cash paid for contingent consideration — — (145 ) — (145 ) Proceeds from issuance of common stock, net of issuance costs 11,124 — — — 11,124 Proceeds from issuance of long-term debt — — 325 — 325 Payments on long-term debt (17,030 ) — (245 ) — (17,275 ) Net payments under revolving credit facilities — — (127 ) — (127 ) Cash paid for dividends (5,323 ) — — — (5,323 ) Cash paid for employee taxes related to shares withheld (1,291 ) (99 ) (20 ) — (1,410 ) Principal payments on capital lease obligations — (659 ) (448 ) — (1,107 ) Net cash used in financing activities (12,521 ) (758 ) (660 ) — (13,939 ) Foreign exchange effect on cash and cash equivalents — 160 2,660 — 2,820 Net increase (decrease) in cash and cash equivalents (42,082 ) (16,668 ) 47,213 — (11,537 ) Cash and cash equivalents, beginning of period 139,153 21,150 341,897 — 502,200 Cash and cash equivalents, end of period $ 97,071 $ 4,482 $ 389,110 $ — $ 490,663

Basis of Presentation of Fina27

Basis of Presentation of Financial Information (Policies)	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation of Financial Information	The accompanying consolidated financial statements of Alere Inc. are unaudited. In the opinion of management, the unaudited consolidated financial statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, for interim financial information and in accordance with the instructions to Form 10-Q Regulation S-X. Form 10-K Our operating segments are currently (i) professional diagnostics; (ii) consumer diagnostics; and (iii) other non-reportable. 10-K 10-K 10-Q, non-reportable pre-established The consolidated financial statements include the accounts of Alere Inc. and its subsidiaries. Intercompany transactions and balances are eliminated and net earnings are reduced by the portion of the net earnings of subsidiaries applicable to non-controlling interests. Certain amounts presented may not recalculate directly, due to rounding.
Cash and Cash Equivalents	We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At March 31, 2017, our cash equivalents consisted of money market funds.
Recently Issued Standards	Recently Issued Standards In March 2017, the FASB issued ASU No. 2017-07, 2017-07. 2017-07 2017-07 2017-07 In January 2017, the FASB issued ASU No. 2017-04, Intangibles — Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment 2017-04. 2017-04 2017-04 2017-04 In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business 2017-01. 2017-01 2017-01 ASU 2017-01 In December 2016, the FASB issued ASU No. 2016-20, Technical Corrections and Improvements to Topic 606: Revenue from Contracts with Customers 2016-20. 2016-20 2014-09, 2016-20 2016-20 In December 2016, the FASB issued ASU No. 2016-19, Technical Corrections and Improvements 2016-19. 2016-19 2016-19 2016-19 In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, ASU 2016-18. 2016-18 beginning-of-period end-of-period 2016-18 ASU 2016-18 In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, 2016-16. 2016-16 2016-16 2016-16 In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, 2016-15. 2016-15 zero-coupon 2016-15 ASU 2016-15 In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, 2016-12. 2016-12: 606-10-25-7; non-cash 2016-12 2016-12 In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, 2016-10. 2016-10 2016-10 2016-10 In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), 2016-02. 2016-02 right-of-use 2016-02 ASU 2016-02 In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers 2014-09, 2014-09 one-year 2014-09 We believe that there were no other accounting standards recently issued that had or are expected to have a material impact on our consolidated financial statements. Recently Adopted Standards In March 2016, the FASB issued ASU No. 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting 2016-09. 2016-09 2016-09 2016-09. 2016-09 • All excess tax benefits or tax deficiencies are now recognized as income tax benefit or expense as applicable. Previously, we recorded the benefit or expense to additional paid-in • All cash payments made to taxing authorities on the employees’ behalf for withheld shares are now presented as financing activities on the statement of cash flows. Previously, it was required to be classified within operating activities. This change was applied retrospectively with a reclassification of $1.4 million from operating to financing activities during the three months ended March 31, 2016. We have elected to continue to estimate forfeitures expected to occur to determine the amount of compensation cost to be recognized in each period. None of the other provisions in this guidance had a significant impact on our consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-07, Investments — Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting, 2016-07. 2016-07 step-by-step 2016-07 2016-07 available-for-sale 2016-07 2016-07. 2016-07 In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, ASU 2015-11. 2015-11 in-scope ASU 2015-11 2015-11 2015-11. 2015-11

Restatement of Previously Iss28

Restatement of Previously Issued Financial Statements (Tables)	3 Months Ended
	Mar. 31, 2017
Accounting Changes and Error Corrections [Abstract]
Restated Consolidated Statements of Operations	ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended March 31, 2016 As Previously Restatement As Restated Net product sales $ 459,771 $ 8,731 $ 468,502 Services revenue 115,709 — 115,709 Net product sales and services revenue 575,480 8,731 584,211 License and royalty revenue 2,729 — 2,729 Net revenue 578,209 8,731 586,940 Cost of net product sales 237,461 3,863 241,324 Cost of services revenue 73,100 — 73,100 Cost of net product sales and services revenue 310,561 3,863 314,424 Cost of license and royalty revenue 1,391 — 1,391 Cost of net revenue 311,952 3,863 315,815 Gross profit 266,257 4,868 271,125 Operating expenses: — Research and development 27,062 — 27,062 Sales and marketing 99,813 827 100,640 General and administrative 114,956 — 114,956 Impairment and (gain) loss on dispositions, net (3,810 ) — (3,810 ) Operating income 28,236 4,041 32,277 Interest expense, including amortization of original issue discounts and deferred financing costs (42,106 ) — (42,106 ) Other (expense) income, net (1,349 ) — (1,349 ) Loss from operations before provision (benefit) for income taxes (15,219 ) 4,041 (11,178 ) Provision (benefit) for income taxes (208 ) 36 (172 ) (Loss) income from operations before equity earnings of unconsolidated entities, net of tax (15,011 ) 4,005 (11,006 ) Equity earnings of unconsolidated entities, net of tax 5,034 — 5,034 Net (loss) income (9,977 ) 4,005 (5,972 ) Less: Net income attributable to non-controlling 103 — 103 Net (loss) income attributable to Alere Inc. and Subsidiaries (10,080 ) 4,005 (6,075 ) Preferred stock dividends (5,309 ) — (5,309 ) Net (loss) income available to common stockholders $ (15,389 ) $ 4,005 $ (11,384 ) Basic and Diluted net income (loss) per common share: Net (loss) income per common share $ (0.18 ) $ 0.05 $ (0.13 ) Weighted-average shares —basic and diluted 86,646 — 86,646 (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter.
Restated Consolidated Statement of Comprehensive Income (Loss)	Three Months Ended March 31, 2016 As Previously Restatement As Restated Comprehensive income attributable to Alere Inc. and Subsidiaries $ 12,268 $ 4,005 $ 16,273 (1) The restatement adjustment to total comprehensive income (loss) attributable to Alere Inc. and Subsidiaries is comprised solely of the restatement adjustment to net income (loss) for the period.
Restated Consolidated Statements of Cash Flows	CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, except per share amounts) (unaudited) Three Months Ended March 31, 2016 As Previously Restatement As Restated Cash Flows from Operating Activities: Net loss $ (9,977 ) $ 4,005 $ (5,972 ) Adjustments to reconcile loss from operations to net cash (used in) provided by operating activities: Non-cash 2,236 — 2,236 Depreciation and amortization 72,504 — 72,504 Non-cash 9,602 — 9,602 Impairment of inventory 1,349 — 1,349 Impairment of long-lived assets 608 — 608 Loss on sale of fixed assets 323 — 323 Equity earnings of unconsolidated entities, net of tax (5,034 ) — (5,034 ) Deferred income taxes (6,812 ) — (6,812 ) Gain on business dispositions (3,810 ) — (3,810 ) Other non-cash 2,496 — 2,496 Non-cash 142 — 142 Changes in assets and liabilities, net of acquisitions: Accounts receivable, net (9,199 ) (8,731 ) (17,930 ) Inventories, net (14,147 ) 3,863 (10,284 ) Prepaid expenses and other current assets (5,796 ) 21 (5,775 ) Accounts payable (31,542 ) — (31,542 ) Accrued expenses and other current liabilities (6,003 ) 821 (5,182 ) Other non-current 14 21 35 Cash paid for contingent consideration (143 ) — (143 ) Net cash (used in) provided by operating activities (3,189 ) — (3,189 ) Cash Flows from Investing Activities: Increase in restricted cash (436 ) — (436 ) Purchases of property, plant and equipment (14,504 ) — (14,504 ) Proceeds from sale of property, plant and equipment 612 — 612 Cash received from business disposition, net of cash divested 21,470 — 21,470 Cash paid for business acquisitions, net of cash acquired (5,945 ) — (5,945 ) Cash received from sales of marketable securities 93 — 93 Cash received from equity method investments 2,205 — 2,205 Cash paid for equity investments (184 ) — (184 ) Decrease in other assets (540 ) — (540 ) Net cash (used in) provided by investing activities 2,771 — 2,771 Cash Flows from Financing Activities: Cash paid for financing costs (1 ) — (1 ) Cash paid for contingent consideration (145 ) — (145 ) Proceeds from issuance of common stock, net of issuance costs 11,124 — 11,124 Proceeds from issuance of long-term debt 325 — 325 Payments on long-term debt (17,275 ) — (17,275 ) Net payments under revolving credit facilities (127 ) — (127 ) Cash paid for dividends (5,323 ) — (5,323 ) Cash paid for employee taxes related to shares withheld (1,410 ) — (1,410 ) Principal payments on capital lease obligations (1,107 ) — (1,107 ) Net cash used in financing activities (13,939 ) — (13,939 ) Foreign exchange effect on cash and cash equivalents 2,820 — 2,820 Net decrease in cash and cash equivalents (11,537 ) — (11,537 ) Cash and cash equivalents, beginning of period 502,200 — 502,200 Cash and cash equivalents, end of period $ 490,663 $ — $ 490,663 (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and such amounts have been revised from the figures presented in such Quarterly Report on Form 10-Q as a result of the retrospective adoption of ASU 2016-09, which reclassified $1,410 of employee taxes related to shares withheld from operating activities to financing activities. (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the misstatements in the classification of certain amounts between current assets, noncurrent assets and current liabilities.

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Inventories are Stated at Lower of Cost (First In, First Out) or Market	Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): March 31, 2017 December 31, 2016 Raw materials $ 103,838 $ 97,652 Work-in-process 68,471 69,086 Finished goods 150,164 142,182 $ 322,473 $ 308,920

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation Expense	We recorded stock-based compensation expense in our consolidated statements of operations for the three months ended March 31, 2017 and 2016 as follows (in thousands): Three Months Ended March 31, 2017 2016 Cost of net revenue $ 396 $ 479 Research and development 384 398 Sales and marketing 1,854 1,925 General and administrative 7,729 6,800 10,363 9,602 Benefit for income taxes 493 — Stock-based compensation, net of tax $ 10,856 $ 9,602

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Common Share	The following table sets forth the computation of basic and diluted net loss per common share for the three months ended March 31, 2017 and 2016 (in thousands, except per share amounts): Three Months Ended March 31, 2017 2016 (As Basic and diluted net loss per common share: Numerator: Loss from operations $ (64,129 ) $ (5,972 ) Preferred stock dividends (5,250 ) (5,309 ) Loss from operations attributable to common shares (69,379 ) (11,281 ) Less: Net income attributable to non-controlling 183 103 Net loss available to common stockholders $ (69,562 ) (11,384 ) Denominator: Weighted-average common shares outstanding – basic and diluted 87,221 $ 86,646 Basic and diluted net loss per common share: Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries $ (0.80 ) $ (0.13 )
Potential Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Common Share	The following potential dilutive securities were not included in the calculation of diluted net loss per common share because the inclusion thereof would be antidilutive (in thousands): Three Months Ended March 31, 2017 2016 Denominator: Options to purchase shares of common stock 6,322 7,378 Conversion shares related to 3% convertible senior subordinated notes — 3,411 Conversion shares related to Series B convertible preferred stock 10,238 10,239 Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding 16,560 21,028

Stockholders' Equity and Non-32

Stockholders' Equity and Non-Controlling Interests (Tables)	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Summary of Changes in Stockholders' Equity and Non-Controlling Interests Comprising Total Equity	A summary of the changes in stockholders’ equity and non-controlling Three Months Ended March 31, 2017 Total Stockholders’ Equity Non- controlling Interests Total Equity Equity, beginning of period $ 1,826,992 $ 4,615 $ 1,831,607 Issuance of common stock under employee compensation plans 424 — 424 Surrender of common stock to settle taxes on restricted stock units (5,582 ) — (5,582 ) Preferred stock dividends (5,323 ) — (5,323 ) Stock-based compensation expense 10,363 — 10,363 Other adjustments — 4 4 Net income (loss) (64,312 ) 183 (64,129 ) Total other comprehensive income 53,259 — 53,259 Equity, end of period $ 1,815,821 $ 4,802 $ 1,820,623

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Summary of Aggregate Purchase Price Allocation	A summary of the fair values of the net assets acquired from EDTS is as follows (in thousands): Fair Value Current assets $ 1,371 Property, plant and equipment 115 Goodwill 2,060 Intangible assets 4,220 Total assets acquired $ 7,766 Current liabilities $ 368 Non-current 928 Total liabilities assumed $ 1,296 Net assets acquired $ 6,470 Cash paid $ 6,470
Intangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives	The following table provides information regarding the intangible assets acquired in connection with the EDTS acquisition and their respective fair values and weighted-average useful lives (dollars in thousands): Fair Value Weighted- average Useful Life Core technology and patents $ 540 10.0 years Trademarks and trade names 310 20.0 years Customer relationships 2,800 14.0 years Non-compete 570 3.0 years Total intangible assets $ 4,220

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2017
Restructuring and Related Activities [Abstract]
Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income	The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three months ended March 31, 2017 and 2016 (in thousands): Three Months Ended March 31, Statement of Operations Caption 2017 2016 Cost of net revenue $ 815 $ 1,267 Research and development 127 1,920 Sales and marketing 10 650 General and administrative 2,078 3,826 Total operating expenses 3,030 7,663 Interest expense, including amortization of original issue discounts and deferred financing costs 1 5 Total charges $ 3,031 $ 7,668
Restructuring Activities Related to Restructuring Plans	The following table summarizes the restructuring activities, for the three months ended March 31, 2017 and 2016 and since inception for all restructuring plans adopted by us, including the 2016 restructuring plan. Our earlier restructuring plans are disclosed in Note 23 to the condensed consolidated financial statements included in our Annual Report on Form 10-K Three Months Ended March 31, Since 2017 2016 Inception Professional Diagnostics Severance-related costs $ 678 $ 3,091 $ 48,101 Facility and transition costs 443 981 16,378 Other exit costs 1 5 834 Cash charges 1,122 4,077 65,313 Fixed asset and inventory impairments — 398 17,951 Other non-cash — 213 2,160 Total professional diagnostics charges $ 1,122 $ 4,688 $ 85,424 Corporate and Other Severance-related costs $ 1 $ 15 $ 4,624 Facility and transition costs 1,908 2,965 34,879 Total corporate and other charges $ 1,909 $ 2,980 $ 39,503 Total restructuring charges $ 3,031 $ 7,668 $ 124,927
Cash Activity for Restructuring Reserves	The following table summarizes our restructuring reserves related to the plans described above, of which $6.4 million is included in accrued expenses and other current liabilities and $0.3 million is included in other long-term liabilities on our accompanying consolidated balance sheets (in thousands): Severance- Facility and Other Exit Total Balance, December 31, 2016 $ 3,339 $ 7,512 $ 39 $ 10,890 Charges 679 2,351 1 3,031 Payments (766 ) (6,443 ) (40 ) (7,249 ) Currency adjustments 15 20 — 35 Balance, March 31, 2017 $ 3,267 $ 3,440 $ — $ 6,707

Long-term Debt (Tables)

Long-term Debt (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Long-Term Debt Balances Outstanding	We had the following long-term debt balances outstanding as of March 31, 2017 and December 31, 2016 (in thousands): March 31, 2017 December 31, 2016 A term loans (1)(2)(3) $ 538,372 $ 544,745 B term loans (1)(2)(3) 950,756 952,664 Revolving loans (1)(2)(3) 125,000 125,000 7.25% Senior notes (2)(3)(4) 443,924 442,709 6.5% Senior subordinated notes (2)(3) 415,813 415,102 6.375% Senior subordinated notes (2)(3) 413,300 412,831 Other lines of credit 1,202 1,124 Other 46,465 46,400 2,934,832 2,940,575 Less: Short-term debt and current portion of long-term debt (82,506 ) (82,370 ) Long-term debt $ 2,852,326 $ 2,858,205 (1) Incurred under our secured credit facility entered into on June 18, 2015. (2) As discussed more fully in Item 2. “ Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources, 10-K 10-Q Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources, Form 10-Q Form 10-Q 10-Q (3) As discussed more fully below, due to our failure to timely file our Annual Report on Form 10-K Form 10-K (4) The 7.25% senior notes mature on July 1, 2018, unless earlier redeemed. Upon maturity, we will be required to pay the principal amount of $450 million, plus all accrued and unpaid interest. Management expects that the acquisition of Alere by Abbott pursuant to the terms of the Amended Merger Agreement will take place prior to the maturity date of July 1, 2018 and, if this expectation is correct, the holders of the 7.25% senior notes will have the rights set forth in connection with such transaction as set forth below in this paragraph. In the event that the transactions contemplated by the Amended Merger Agreement do not close, we expect that we would be able to pay such principal and accrued interest by one or a combination of the following: refinancing such indebtedness as we have done in the past, using available cash resources, or utilizing amounts available under the revolving credit facility. If a change of control occurs, subject to specified conditions, we must give holders of the 7.25% senior notes an opportunity to sell their notes to us at a purchase price of 101% of the principal amount of the notes, plus accrued and unpaid interest to (but excluding) the date of the purchase. The merger under the Amended Merger Agreement, as described in Note 3 above will, if consummated, constitute a change of control under the indenture governing the 7.25% senior notes.
Long-Term Debt Interest Expense	In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for the three months ended March 31, 2017 and 2016 as follows (in thousands): Three Months Ended March 31, 2017 2016 Secured credit facility (1)(2) $ 18,730 $ 17,043 7.25% Senior notes (2) 9,372 8,524 6.375% Senior subordinated notes (2) 7,242 7,003 6.5% Senior subordinated notes (2) 7,617 7,231 3% Convertible senior subordinated notes — 1,244 Other 222 1,061 $ 43,183 $ 42,106 (1) Includes “A” term loans, “B” term loans, and revolving line of credit loans. (2) For the three months ended March 31, 2017, the amounts include $2.1 million related to the amortization of fees paid for certain debt modifications, of which there were none in the same period of 2016.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques	The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2017 and December 31, 2016, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): Description March 31, 2017 Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 540 $ 540 $ — $ — Total assets $ 540 $ 540 $ — $ — Liabilities: Contingent consideration obligations (1) $ 43,400 $ — $ — $ 43,400 Total liabilities $ 43,400 $ — $ — $ 43,400 Description December 31, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 76 $ 76 $ — $ — Total assets $ 76 $ 76 $ — $ — Liabilities: Contingent consideration obligations (1) $ 43,200 $ — $ — $ 43,200 Total liabilities $ 43,200 $ — $ — $ 43,200 (1) We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out earn-out Commitments and Contingences
Changes in Fair Value of Contingent Consideration Obligations	Changes in the fair value of our Level 3 contingent consideration obligations during the three months ended March 31, 2017 were as follows (in thousands): Fair value of contingent consideration obligations, December 31, 2016 $ 43,200 Payments (287 ) Fair value adjustments 489 Foreign currency adjustments (2 ) Fair value of contingent consideration obligations, March 31, 2017 $ 43,400

Financial Information by Segm37

Financial Information by Segment (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Performance of Our Operating Segments Based on Revenue and Operating Income (Loss)	Segment information for the three months ended March 31, 2017 and 2016 is as follows (in thousands): Professional Consumer Other Non- Reportable Corporate Total Three Months Ended March 31, 2017: Net revenue $ 534,317 $ 17,240 $ 36,659 $ — $ 588,216 Operating income (loss) $ 88,957 $ 71 $ 6,616 $ (100,666 ) $ (5,022 ) Depreciation and amortization $ 54,289 $ 1,155 $ 3,188 $ 2,302 $ 60,934 Restructuring charge $ 1,122 $ — $ — $ 1,909 $ 3,031 Stock-based compensation $ — $ — $ — $ 10,363 $ 10,363 Professional Consumer Other Non- Reportable Corporate Total Three Months Ended March 31, 2016: Net revenue, as restated $ 534,513 $ 17,442 $ 34,985 $ — $ 586,940 Operating income (loss), as restated $ 80,356 $ 167 $ 6,238 $ (54,484 ) $ 32,277 Depreciation and amortization $ 63,673 $ 1,499 $ 5,159 $ 2,173 $ 72,504 Restructuring charge $ 4,688 $ — $ — $ 2,980 $ 7,668 Stock-based compensation $ — $ — $ — $ 9,602 $ 9,602 Assets: As of March 31, 2017 $ 5,170,280 $ 177,686 $ 88,366 $ 237,537 $ 5,673,869 As of December 31, 2016 $ 5,199,806 $ 175,362 $ 87,193 $ 185,918 $ 5,648,279
Summary of Company's Net Revenue from Professional Diagnostics Reporting Segments by Groups of Similar Products and Services	The following table summarizes our net revenue from the professional diagnostics reporting segment by groups of similar products and services for the three months ended March 31, 2017 and 2016 (in thousands): Three Months Ended March 31, 2017 2016 (As Restated) Cardiometabolic $ 125,176 $ 159,663 Infectious disease 222,934 191,956 Toxicology 150,637 146,783 Other 32,928 33,382 Total professional diagnostics net product sales and services revenue 531,675 531,784 License and royalty revenue 2,642 2,729 Total professional diagnostics net revenue $ 534,317 $ 534,513

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Balances with SPD within Consolidated Balance Sheets	The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): Balance Sheet Caption March 31, 2017 December 31, 2016 Accounts receivable, net of allowances $ 7,104 $ 7,855 Prepaid expenses and other current assets $ 8,231 $ 7,486 Other non-current $ 6,228 $ 6,122 Accounts payable $ 32,413 $ 34,216

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions	The following table summarizes our contractual contingent purchase price consideration obligations related to certain of our acquisitions (in thousands): Acquisition Acquisition Date Acquisition Date Fair Value Maximum Remaining Earn-out Potential as of March 31, 2017 Remaining Earn-out Period as of March 31, 2017 Estimated Fair Value as of March 31, 2017 Estimated Fair Value as of December 31, 2016 Payments Made During 2017 TwistDx, Inc. (1) March 11, 2010 $ 35,600 $ 102,535 2017 – 2025 (3) $ 36,300 $ 35,700 $ 159 Epocal (2) February 1, 2013 $ 75,000 $ 15,375 2017 – 2018 3,000 3,000 — Other Various $ 30,373 $ — 4,100 4,500 128 $ 43,400 $ 43,200 $ 287 (1) The terms of the acquisition agreement require us to pay earn-outs upon successfully meeting certain revenue and product development targets through 2025. (2) The terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. (3) The maximum earn-out

Equity Investments (Tables)

Equity Investments (Tables)	3 Months Ended
	Mar. 31, 2017
Financial Information Combined Condensed Results of Operations	CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended March 31, 2017 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 263,294 $ 272,910 $ (72,759 ) $ 463,445 Services revenue — 109,531 12,598 — 122,129 Net product sales and services revenue — 372,825 285,508 (72,759 ) 585,574 License and royalty revenue — 3,730 854 (1,942 ) 2,642 Net revenue — 376,555 286,362 (74,701 ) 588,216 Cost of net product sales 1,139 131,757 161,862 (64,927 ) 229,831 Cost of services revenue 45 76,484 7,588 (8,218 ) 75,899 Cost of net product sales and services revenue 1,184 208,241 169,450 (73,145 ) 305,730 Cost of license and royalty revenue — — 2,702 (1,942 ) 760 Cost of net revenue 1,184 208,241 172,152 (75,087 ) 306,490 Gross profit (loss) (1,184 ) 168,314 114,210 386 281,726 Operating expenses: Research and development 1,220 17,890 7,174 — 26,284 Sales and marketing 1,925 48,344 43,922 — 94,191 General and administrative 94,300 34,522 37,764 (313 ) 166,273 Impairment and (gain) loss on dispositions, net — — — — — Operating income (loss) (98,629 ) 67,558 25,350 699 (5,022 ) Interest expense, including amortization of original issue discounts and deferred financing costs (42,961 ) (1,877 ) (2,278 ) 3,933 (43,183 ) Other income (expense), net 2,577 1,552 (2,711 ) (3,934 ) (2,516 ) Income (loss) before provision for income taxes (139,013 ) 67,233 20,361 698 (50,721 ) Provision for income taxes 13,547 — 5,062 — 18,609 Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax (152,560 ) 67,233 15,299 698 (69,330 ) Equity in earnings of subsidiaries, net of tax 88,202 — — (88,202 ) — Equity earnings of unconsolidated entities, net of tax 229 — 4,972 — 5,201 Net income (loss) (64,129 ) 67,233 20,271 (87,504 ) (64,129 ) Less: Net income attributable to non-controlling — — 183 — 183 Net income (loss) attributable to Alere Inc. and Subsidiaries (64,129 ) 67,233 20,088 (87,504 ) (64,312 ) Preferred stock dividends (5,250 ) — — — (5,250 ) Net income (loss) available to common stockholders $ (69,379 ) $ 67,233 $ 20,088 $ (87,504 ) $ (69,562 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended March 31, 2016 (As Restated) (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 224,380 $ 305,568 $ (61,446 ) $ 468,502 Services revenue — 104,484 11,225 — 115,709 Net product sales and services revenue — 328,864 316,793 (61,446 ) 584,211 License and royalty revenue — 2,920 2,558 (2,749 ) 2,729 Net revenue — 331,784 319,351 (64,195 ) 586,940 Cost of net product sales 114 124,758 169,845 (53,393 ) 241,324 Cost of services revenue — 72,495 8,040 (7,435 ) 73,100 Cost of net product sales and services revenue 114 197,253 177,885 (60,828 ) 314,424 Cost of license and royalty revenue — 17 4,123 (2,749 ) 1,391 Cost of net revenue 114 197,270 182,008 (63,577 ) 315,815 Gross profit (loss) (114 ) 134,514 137,343 (618 ) 271,125 Operating expenses: Research and development 4,134 14,459 8,469 — 27,062 Sales and marketing 1,336 54,465 44,839 — 100,640 General and administrative 44,615 33,186 37,155 — 114,956 Impairment and (gain) loss on dispositions, net — — (3,810 ) — (3,810 ) Operating income (loss) (50,199 ) 32,404 50,690 (618 ) 32,277 Interest expense, including amortization of original issue discounts and deferred financing costs (41,087 ) (2,652 ) (3,067 ) 4,700 (42,106 ) Other income (expense), net 1,988 2,502 (1,139 ) (4,700 ) (1,349 ) Income (loss) before provision (benefit) for income taxes (89,298 ) 32,254 46,484 (618 ) (11,178 ) Provision (benefit) for income taxes (54 ) 250 (368 ) — (172 ) Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax (89,244 ) 32,004 46,852 (618 ) (11,006 ) Equity in earnings of subsidiaries, net of tax 82,591 — — (82,591 ) — Equity earnings of unconsolidated entities, net of tax 681 — 4,581 (228 ) 5,034 Net income (loss) (5,972 ) 32,004 51,433 (83,437 ) (5,972 ) Less: Net income attributable to non-controlling — — 103 — 103 Net income (loss) attributable to Alere Inc. and Subsidiaries (5,972 ) 32,004 51,330 (83,437 ) (6,075 ) Preferred stock dividends (5,309 ) — — — (5,309 ) Net income (loss) available to common stockholders $ (11,281 ) $ 32,004 $ 51,330 $ (83,437 ) $ (11,384 )
Financial Information Combined Condensed Balance Sheet	CONSOLIDATING BALANCE SHEET March 31, 2017 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 215,718 $ 4,168 $ 381,586 $ — $ 601,472 Restricted cash 814 — 52,329 — 53,143 Marketable securities — 83 457 — 540 Accounts receivable, net of allowances — 182,775 204,912 — 387,687 Inventories, net — 162,740 183,813 (24,080 ) 322,473 Prepaid expenses and other current assets 21,817 23,570 67,839 4,602 117,828 Intercompany receivables 383,305 1,106,663 110,136 (1,600,104 ) — Total current assets 621,654 1,479,999 1,001,072 (1,619,582 ) 1,483,143 Property, plant and equipment, net 23,061 241,058 180,798 (5,115 ) 439,802 Goodwill — 1,823,446 957,654 — 2,781,100 Other intangible assets with indefinite lives — 7,472 14,705 (59 ) 22,118 Finite-lived intangible assets, net 2,362 487,478 298,425 (3,200 ) 785,065 Restricted cash — — 2,355 — 2,355 Other non-current 463 1,739 12,946 (808 ) 14,340 Investments in subsidiaries 3,554,484 158,631 57,651 (3,770,766 ) — Investments in unconsolidated entities 875 14,765 47,932 15,655 79,227 Deferred tax assets — — 59,811 (37,336 ) 22,475 Non-current 4,580 — 39,664 — 44,244 Intercompany notes receivables 1,677,641 633,767 3,000 (2,314,408 ) — Total assets $ 5,885,120 $ 4,848,355 $ 2,676,013 $ (7,735,619 ) $ 5,673,869 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 40,073 $ 4 $ 42,429 $ — $ 82,506 Current portion of capital lease obligations — 1,433 1,468 — 2,901 Accounts payable 56,545 77,416 77,469 — 211,430 Accrued expenses and other current liabilities 146,351 133,109 171,964 (34,977 ) 416,447 Intercompany payables 505,213 860,907 233,912 (1,600,032 ) — Total current liabilities 748,182 1,072,869 527,242 (1,635,009 ) 713,284 Long-term liabilities: Long-term debt, net of current portion 2,847,092 — 5,234 — 2,852,326 Capital lease obligations, net of current portion — 1,732 4,942 — 6,674 Deferred tax liabilities — 61,928 58,817 81 120,826 Other long-term liabilities 94,324 44,941 21,679 (808 ) 160,136 Intercompany notes payables 379,701 1,188,611 746,096 (2,314,408 ) — Total long-term liabilities 3,321,117 1,297,212 836,768 (2,315,135 ) 3,139,962 Total stockholders’ equity 1,815,821 2,478,274 1,307,201 (3,785,475 ) 1,815,821 Non-controlling — — 4,802 — 4,802 Total equity 1,815,821 2,478,274 1,312,003 (3,785,475 ) 1,820,623 Total liabilities and equity $ 5,885,120 $ 4,848,355 $ 2,676,013 $ (7,735,619 ) $ 5,673,869 CONSOLIDATING BALANCE SHEET December 31, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 167,639 $ 3,161 $ 396,415 $ — $ 567,215 Restricted cash 1,337 — 50,213 — 51,550 Marketable securities — 76 — — 76 Accounts receivable, net of allowances — 186,067 227,468 — 413,535 Inventories, net — 168,736 163,967 (23,783 ) 308,920 Prepaid expenses and other current assets 15,983 22,318 68,748 11,558 118,607 Intercompany receivables 390,328 1,008,767 204,587 (1,603,682 ) — Total current assets 575,287 1,389,125 1,111,398 (1,615,907 ) 1,459,903 Property, plant and equipment, net 25,525 243,755 176,618 (4,708 ) 441,190 Goodwill — 1,822,290 937,076 — 2,759,366 Other intangible assets with indefinite lives — 7,457 19,765 (58 ) 27,164 Finite-lived intangible assets, net 2,490 507,060 299,227 (3,200 ) 805,577 Restricted cash — — 2,171 — 2,171 Other non-current 509 2,267 13,060 (870 ) 14,966 Investments in subsidiaries 3,409,001 158,195 57,650 (3,624,846 ) — Investments in unconsolidated entities 684 14,765 42,523 14,253 72,225 Deferred tax assets — — 57,819 (37,336 ) 20,483 Non-current 4,580 — 40,654 — 45,234 Intercompany notes receivables 1,757,723 709,965 744 (2,468,432 ) — Total assets $ 5,775,799 $ 4,854,879 $ 2,758,705 $ (7,741,104 ) $ 5,648,279 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 40,072 $ — $ 42,298 $ — $ 82,370 Current portion of capital lease obligations — 1,560 1,504 — 3,064 Accounts payable 35,591 78,981 81,307 — 195,879 Accrued expenses and other current liabilities 65,582 133,506 223,778 (28,023 ) 394,843 Intercompany payables 485,573 859,924 258,154 (1,603,651 ) — Total current liabilities 626,818 1,073,971 607,041 (1,631,674 ) 676,156 Long-term liabilities: Long-term debt, net of current portion 2,852,978 — 5,227 — 2,858,205 Capital lease obligations, net of current portion — 2,029 5,192 — 7,221 Deferred tax liabilities — 51,314 67,702 82 119,098 Other long-term liabilities 91,042 44,563 21,257 (870 ) 155,992 Intercompany notes payables 377,969 1,274,419 816,044 (2,468,432 ) — Total long-term liabilities 3,321,989 1,372,325 915,422 (2,469,220 ) 3,140,516 Total stockholders’ equity 1,826,992 2,408,583 1,231,627 (3,640,210 ) 1,826,992 Non-controlling — — 4,615 — 4,615 Total equity 1,826,992 2,408,583 1,236,242 (3,640,210 ) 1,831,607 Total liabilities and equity $ 5,775,799 $ 4,854,879 $ 2,758,705 $ (7,741,104 ) $ 5,648,279
Swiss Precision Diagnostics And TechLab [Member]
Financial Information Combined Condensed Results of Operations	Summarized financial information for SPD (and TechLab on a combined basis for the three months ended March 31, 2016) is as follows (in thousands): Three Months Ended March 31, Combined Condensed Results of Operations: 2017 2016 Net revenue $ 45,392 $ 53,434 Gross profit $ 35,133 $ 36,219 Net income after taxes $ 10,048 $ 10,141
Financial Information Combined Condensed Balance Sheet	Combined Condensed Balance Sheet: March 31, 2017 December 31, 2016 Current assets $ 85,888 $ 75,248 Non-current 21,246 20,578 Total assets $ 107,134 $ 95,826 Current liabilities $ 43,890 $ 44,234 Non-current 3,945 3,875 Total liabilities $ 47,835 $ 48,109

Guarantor Financial Informati41

Guarantor Financial Information (Tables)	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Guarantor Financial Information Consolidating Statement of Comprehensive Income (Loss)	CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended March 31, 2017 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ (64,129 ) $ 67,233 $ 20,271 $ (87,504 ) $ (64,129 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 27 164 53,180 (41 ) 53,330 Minimum pension liability adjustment — — (71 ) — (71 ) Other comprehensive income, before tax 27 164 53,109 (41 ) 53,259 Other comprehensive income 27 164 53,109 (41 ) 53,259 Comprehensive income (loss) (64,102 ) 67,397 73,380 (87,545 ) (10,870 ) Less: Comprehensive income attributable to non-controlling — — 183 — 183 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (64,102 ) $ 67,397 $ 73,197 $ (87,545 ) $ (11,053 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended March 31, 2016 (As Restated) (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ (5,972 ) $ 32,004 $ 51,433 $ (83,437 ) $ (5,972 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 115 (129 ) 22,207 — 22,193 Minimum pension liability adjustment — — 155 — 155 Other comprehensive income (loss), before tax 115 (129 ) 22,362 — 22,348 Other comprehensive income (loss) 115 (129 ) 22,362 — 22,348 Comprehensive income (loss) (5,857 ) 31,875 73,795 (83,437 ) 16,376 Less: Comprehensive income attributable to non-controlling — — 103 — 103 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (5,857 ) $ 31,875 $ 73,692 $ (83,437 ) $ 16,273
Guarantor Financial Information Consolidating Statement of Cash Flows	CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2017 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (64,129 ) $ 67,233 $ 20,271 $ (87,504 ) $ (64,129 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (88,202 ) — — 88,202 — Non-cash 4,251 1 29 — 4,281 Depreciation and amortization 2,390 37,398 21,384 (238 ) 60,934 Non-cash 6,241 1,857 2,265 — 10,363 Impairment of long-lived assets — (342 ) — — (342 ) Loss on sales of fixed assets — 2,222 119 — 2,341 Equity earnings of unconsolidated entities, net of tax (229 ) — (4,972 ) — (5,201 ) Deferred income taxes 2,252 — (5,629 ) — (3,377 ) Other non-cash 286 102 1,172 4 1,564 Non-cash — 759 (270 ) — 489 Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — 3,815 29,290 — 33,105 Inventories, net — (3,207 ) (15,605 ) (460 ) (19,272 ) Prepaid expenses and other current assets (5,982 ) (1,409 ) 4,186 6,955 3,750 Accounts payable 21,415 (1,170 ) (6,882 ) — 13,363 Accrued expenses and other current liabilities 78,365 494 (54,191 ) (6,954 ) 17,714 Other non-current 921 9,665 (4,934 ) — 5,652 Cash paid for contingent consideration — (159 ) — — (159 ) Intercompany payable (receivable) 111,553 (109,644 ) (2,158 ) 249 — Net cash provided by (used in) operating activities 69,132 7,615 (15,925 ) 254 61,076 Cash Flows from Investing Activities: (Increase) decrease in restricted cash 523 — (1,968 ) — (1,445 ) Purchases of property, plant and equipment (624 ) (5,143 ) (4,942 ) 310 (10,399 ) Proceeds from sale of property, plant and equipment — 3 446 (310 ) 139 Cash paid for business acquisitions, net of cash acquired (3,100 ) 40 — — (3,060 ) Cash received from sales of marketable securities — (7 ) — — (7 ) Cash paid for equity investments (191 ) — (41 ) — (232 ) Proceeds from sale of equity investments 229 — — — 229 Decrease in other assets 47 4 31 — 82 Net cash provided by (used in) investing activities (3,116 ) (5,103 ) (6,474 ) — (14,693 ) Cash Flows from Financing Activities: Cash paid for contingent consideration — — (128 ) — (128 ) Proceeds from issuance of common stock, net of issuance costs 496 — — — 496 Payments on long-term debt (10,018 ) — (140 ) — (10,158 ) Net proceeds (payments) under revolving credit facilities — — 48 — 48 Cash paid for dividends (5,323 ) — — — (5,323 ) Cash paid for employee taxes related to shares withheld (3,092 ) (1,095 ) (1,414 ) — (5,601 ) Principal payments on capital lease obligations — (424 ) (428 ) — (852 ) Net cash used in financing activities (17,937 ) (1,519 ) (2,062 ) — (21,518 ) Foreign exchange effect on cash and cash equivalents — 14 9,632 (254 ) 9,392 Net increase (decrease) in cash and cash equivalents 48,079 1,007 (14,829 ) — 34,257 Cash and cash equivalents, beginning of period 167,639 3,161 396,415 — 567,215 Cash and cash equivalents, end of period $ 215,718 $ 4,168 $ 381,586 $ — $ 601,472 CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2016 (As Restated) (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (5,972 ) $ 32,004 $ 51,433 $ (83,437 ) $ (5,972 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (82,591 ) — — 82,591 — Non-cash 2,188 4 44 — 2,236 Depreciation and amortization 2,203 45,691 23,722 888 72,504 Non-cash 5,069 2,287 2,246 — 9,602 Impairment of inventory — — 1,349 — 1,349 Impairment of long-lived assets — 608 — — 608 Loss on sale of fixed assets 15 8 300 — 323 Equity earnings of unconsolidated entities, net of tax (681 ) — (4,581 ) 228 (5,034 ) Deferred income taxes — (100 ) (6,712 ) — (6,812 ) Gain on business dispositions — — (3,810 ) — (3,810 ) Other non-cash 105 303 2,088 — 2,496 Non-cash (1,000 ) 1,199 (57 ) — 142 Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — (7,875 ) (10,055 ) — (17,930 ) Inventories, net — (6,681 ) (3,333 ) (270 ) (10,284 ) Prepaid expenses and other current assets (1,137 ) 1,514 (6,177 ) 25 (5,775 ) Accounts payable (3,694 ) (6,773 ) (21,075 ) — (31,542 ) Accrued expenses and other current liabilities 10,584 (94,355 ) 78,614 (25 ) (5,182 ) Other non-current 157,791 (159,277 ) 1,583 (62 ) 35 Cash paid for contingent consideration (143 ) — — — (143 ) Intercompany payable (receivable) (111,564 ) 180,953 (69,389 ) — — Net cash provided by (used in) operating activities (28,827 ) (10,490 ) 36,190 (62 ) (3,189 ) Cash Flows from Investing Activities: (Increase) decrease in restricted cash (513 ) — 77 — (436 ) Purchases of property, plant and equipment (841 ) (5,615 ) (8,048 ) — (14,504 ) Proceeds from sale of property, plant and equipment — 40 572 — 612 Cash received from (used in) business dispositions, net of cash divested (1,337 ) — 22,807 — 21,470 Cash paid for business acquisitions, net of cash acquired — — (5,945 ) — (5,945 ) Cash received from sales of marketable securities — 93 — — 93 Cash received from equity method investments 2,205 — — — 2,205 Cash paid for equity investments (184 ) — — — (184 ) Increase in other assets (64 ) (98 ) (440 ) 62 (540 ) Net cash provided by (used in) investing activities (734 ) (5,580 ) 9,023 62 2,771 Cash Flows from Financing Activities: Cash paid for financing costs (1 ) — — — (1 ) Cash paid for contingent consideration — — (145 ) — (145 ) Proceeds from issuance of common stock, net of issuance costs 11,124 — — — 11,124 Proceeds from issuance of long-term debt — — 325 — 325 Payments on long-term debt (17,030 ) — (245 ) — (17,275 ) Net payments under revolving credit facilities — — (127 ) — (127 ) Cash paid for dividends (5,323 ) — — — (5,323 ) Cash paid for employee taxes related to shares withheld (1,291 ) (99 ) (20 ) — (1,410 ) Principal payments on capital lease obligations — (659 ) (448 ) — (1,107 ) Net cash used in financing activities (12,521 ) (758 ) (660 ) — (13,939 ) Foreign exchange effect on cash and cash equivalents — 160 2,660 — 2,820 Net increase (decrease) in cash and cash equivalents (42,082 ) (16,668 ) 47,213 — (11,537 ) Cash and cash equivalents, beginning of period 139,153 21,150 341,897 — 502,200 Cash and cash equivalents, end of period $ 97,071 $ 4,482 $ 389,110 $ — $ 490,663

Basis of Presentation of Fina42

Basis of Presentation of Financial Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	2

Restatement of Previously Iss43

Restatement of Previously Issued Financial Statements - Restated Consolidated Statements of Operations (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales	$ 463,445	$ 468,502	[1]
Services revenue	122,129	115,709	[1]
Net product sales and services revenue	585,574	584,211	[1]
License and royalty revenue	2,642	2,729	[1]
Net revenue	588,216	586,940	[1]
Cost of net product sales	229,831	241,324	[1]
Cost of services revenue	75,899	73,100	[1]
Cost of net product sales and services revenue	305,730	314,424	[1]
Cost of license and royalty revenue	760	1,391	[1]
Cost of net revenue	306,490	315,815	[1]
Gross profit	281,726	271,125	[1]
Operating expenses:
Research and development	26,284	27,062	[1]
Sales and marketing	94,191	100,640	[1]
General and administrative	166,273	114,956	[1]
Impairment and gain on dispositions, net	0	(3,810)	[1]
Operating (loss) income	(5,022)	32,277	[1]
Interest expense, including amortization of original issue discounts and deferred financing costs	(43,183)	(42,106)	[1]
Other (expense) income, net	(2,516)	(1,349)	[1]
Loss from operations before provision (benefit) for income taxes	(50,721)	(11,178)	[1]
Provision (benefit) for income taxes	18,609	(172)	[1]
Loss from operations before equity earnings of unconsolidated entities, net of tax	(69,330)	(11,006)	[1]
Equity earnings of unconsolidated entities, net of tax	5,201	5,034	[1]
Net income (loss)	(64,129)	(5,972)	[1]
Less: Net income attributable to non-controlling interests	183	103	[1]
Net loss attributable to Alere Inc. and Subsidiaries	(64,312)	(6,075)	[1]
Preferred stock dividends	(5,250)	(5,309)	[1]
Net loss available to common stockholders	$ (69,562)	$ (11,384)	[1]
Basic and diluted net loss per common share:
Net loss per common share	$ (0.80)	$ (0.13)	[1]
Weighted-average shares -basic and diluted	87,221	86,646	[1]
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales		$ 459,771
Services revenue		115,709
Net product sales and services revenue		575,480
License and royalty revenue		2,729
Net revenue		578,209
Cost of net product sales		237,461
Cost of services revenue		73,100
Cost of net product sales and services revenue		310,561
Cost of license and royalty revenue		1,391
Cost of net revenue		311,952
Gross profit		266,257
Operating expenses:
Research and development		27,062
Sales and marketing		99,813
General and administrative		114,956
Impairment and gain on dispositions, net		(3,810)
Operating (loss) income		28,236
Interest expense, including amortization of original issue discounts and deferred financing costs		(42,106)
Other (expense) income, net		(1,349)
Loss from operations before provision (benefit) for income taxes		(15,219)
Provision (benefit) for income taxes		(208)
Loss from operations before equity earnings of unconsolidated entities, net of tax		(15,011)
Equity earnings of unconsolidated entities, net of tax		5,034
Net income (loss)		(9,977)
Less: Net income attributable to non-controlling interests		103
Net loss attributable to Alere Inc. and Subsidiaries		(10,080)
Preferred stock dividends		(5,309)
Net loss available to common stockholders		$ (15,389)
Basic and diluted net loss per common share:
Net loss per common share		$ (0.18)
Weighted-average shares -basic and diluted		86,646
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales		$ 8,731
Services revenue		0
Net product sales and services revenue		8,731
License and royalty revenue		0
Net revenue		8,731
Cost of net product sales		3,863
Cost of services revenue		0
Cost of net product sales and services revenue		3,863
Cost of license and royalty revenue		0
Cost of net revenue		3,863
Gross profit		4,868
Operating expenses:
Research and development		0
Sales and marketing		827
General and administrative		0
Impairment and gain on dispositions, net		0
Operating (loss) income		4,041
Interest expense, including amortization of original issue discounts and deferred financing costs		0
Other (expense) income, net		0
Loss from operations before provision (benefit) for income taxes		4,041
Provision (benefit) for income taxes		36
Loss from operations before equity earnings of unconsolidated entities, net of tax		4,005
Equity earnings of unconsolidated entities, net of tax		0
Net income (loss)		4,005
Less: Net income attributable to non-controlling interests		0
Net loss attributable to Alere Inc. and Subsidiaries		4,005
Preferred stock dividends		0
Net loss available to common stockholders		$ 4,005
Basic and diluted net loss per common share:
Net loss per common share		$ 0.05
Weighted-average shares -basic and diluted		0
[1]	As Restated

Restatement of Previously Iss44

Restatement of Previously Issued Financial Statements - Restated Consolidated Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Comprehensive income attributable to Alere Inc. and Subsidiaries	$ (11,053)	$ 16,273	[1]
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Comprehensive income attributable to Alere Inc. and Subsidiaries		12,268
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Comprehensive income attributable to Alere Inc. and Subsidiaries		$ 4,005
[1]	As Restated

Restatement of Previously Iss45

Restatement of Previously Issued Financial Statements - Restated Consolidated Statements of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended			15 Months Ended
	Mar. 31, 2017	Mar. 31, 2016		Jul. 01, 2018
Cash Flows from Operating Activities:
Net loss	$ (64,129)	$ (5,972)	[1]
Adjustments to reconcile loss from operations to net cash (used in) provided by operating activities:
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	4,281	2,236	[1]
Depreciation and amortization	60,934	72,504	[1]
Non-cash stock-based compensation expense	10,363	9,602	[1]
Impairment of inventory	0	1,349	[1]
Impairment of long-lived assets	(342)	608	[1]
Loss on sale of fixed assets	2,341	323	[1]
Equity earnings of unconsolidated entities, net of tax	(5,201)	(5,034)	[1]
Deferred income taxes	(3,377)	(6,812)	[1]
Gain on business dispositions	0	(3,810)	[1]
Other non-cash items	1,564	2,496	[1]
Non-cash change in fair value of contingent consideration	489	142	[1]
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	33,105	(17,930)	[1]
Inventories, net	(19,272)	(10,284)	[1]
Prepaid expenses and other current assets	3,750	(5,775)	[1]
Accounts payable	13,363	(31,542)	[1]
Accrued expenses and other current liabilities	17,714	(5,182)	[1]
Other non-current assets and liabilities		35
Cash paid for contingent consideration	(159)	(143)	[1]
Net cash (used in) provided by operating activities	61,076	(3,189)	[1]
Cash Flows from Investing Activities:
Increase in restricted cash	(1,445)	(436)	[1]
Purchases of property, plant and equipment	(10,399)	(14,504)	[1]
Proceeds from sale of property, plant and equipment	139	612	[1]
Cash received from business disposition, net of cash divested	0	21,470	[1]
Cash paid for business acquisitions, net of cash acquired	(3,060)	(5,945)	[1]
Cash received from sales of marketable securities	(7)	93	[1]
Cash received from equity method investments	0	2,205	[1]
Cash paid for equity investments	(232)	(184)	[1]
Decrease (Increase) in other assets	82	(540)	[1]
Net cash (used in) provided by investing activities	(14,693)	2,771	[1]
Cash Flows from Financing Activities:
Cash paid for financing costs	0	(1)	[1]
Cash paid for contingent consideration	(128)	(145)	[1]
Proceeds from issuance of common stock, net of issuance costs	496	11,124	[1]
Proceeds from issuance of long-term debt	0	325	[1]
Payments on long-term debt	(10,158)	(17,275)	[1]
Net payments under revolving credit facilities	48	(127)	[1]
Cash paid for dividends	(5,323)	(5,323)	[1]
Cash paid for employee taxes related to shares withheld	(5,601)	(1,410)	[1]
Principal payments on capital lease obligations	(852)	(1,107)	[1]
Net cash used in financing activities	(21,518)	(13,939)	[1]
Foreign exchange effect on cash and cash equivalents	9,392	2,820	[1]
Net decrease in cash and cash equivalents	34,257	(11,537)	[1]
Cash and cash equivalents, beginning of period	567,215	502,200	[1]	$ 601,472
Cash and cash equivalents, end of period	$ 601,472	490,663	[1]
As Previously Reported [Member]
Cash Flows from Operating Activities:
Net loss		(9,977)
Adjustments to reconcile loss from operations to net cash (used in) provided by operating activities:
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs		2,236
Depreciation and amortization		72,504
Non-cash stock-based compensation expense		9,602
Impairment of inventory		1,349
Impairment of long-lived assets		608
Loss on sale of fixed assets		323
Equity earnings of unconsolidated entities, net of tax		(5,034)
Deferred income taxes		(6,812)
Gain on business dispositions		(3,810)
Other non-cash items		2,496
Non-cash change in fair value of contingent consideration		142
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net		(9,199)
Inventories, net		(14,147)
Prepaid expenses and other current assets		(5,796)
Accounts payable		(31,542)
Accrued expenses and other current liabilities		(6,003)
Other non-current assets and liabilities		14
Cash paid for contingent consideration		(143)
Net cash (used in) provided by operating activities		(3,189)
Cash Flows from Investing Activities:
Increase in restricted cash		(436)
Purchases of property, plant and equipment		(14,504)
Proceeds from sale of property, plant and equipment		612
Cash received from business disposition, net of cash divested		21,470
Cash paid for business acquisitions, net of cash acquired		(5,945)
Cash received from sales of marketable securities		93
Cash received from equity method investments		2,205
Cash paid for equity investments		(184)
Decrease (Increase) in other assets		(540)
Net cash (used in) provided by investing activities		2,771
Cash Flows from Financing Activities:
Cash paid for financing costs		(1)
Cash paid for contingent consideration		(145)
Proceeds from issuance of common stock, net of issuance costs		11,124
Proceeds from issuance of long-term debt		325
Payments on long-term debt		(17,275)
Net payments under revolving credit facilities		(127)
Cash paid for dividends		(5,323)
Cash paid for employee taxes related to shares withheld		(1,410)
Principal payments on capital lease obligations		(1,107)
Net cash used in financing activities		(13,939)
Foreign exchange effect on cash and cash equivalents		2,820
Net decrease in cash and cash equivalents		(11,537)
Cash and cash equivalents, beginning of period		502,200
Cash and cash equivalents, end of period		490,663
Restatement Adjustment [Member]
Cash Flows from Operating Activities:
Net loss		4,005
Adjustments to reconcile loss from operations to net cash (used in) provided by operating activities:
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs		0
Depreciation and amortization		0
Non-cash stock-based compensation expense		0
Impairment of inventory		0
Impairment of long-lived assets		0
Loss on sale of fixed assets		0
Equity earnings of unconsolidated entities, net of tax		0
Deferred income taxes		0
Gain on business dispositions		0
Other non-cash items		0
Non-cash change in fair value of contingent consideration		0
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net		(8,731)
Inventories, net		3,863
Prepaid expenses and other current assets		21
Accounts payable		0
Accrued expenses and other current liabilities		821
Other non-current assets and liabilities		21
Cash paid for contingent consideration		0
Net cash (used in) provided by operating activities		0
Cash Flows from Investing Activities:
Increase in restricted cash		0
Purchases of property, plant and equipment		0
Proceeds from sale of property, plant and equipment		0
Cash received from business disposition, net of cash divested		0
Cash paid for business acquisitions, net of cash acquired		0
Cash received from sales of marketable securities		0
Cash received from equity method investments		0
Cash paid for equity investments		0
Decrease (Increase) in other assets		0
Net cash (used in) provided by investing activities		0
Cash Flows from Financing Activities:
Cash paid for financing costs		0
Cash paid for contingent consideration		0
Proceeds from issuance of common stock, net of issuance costs		0
Proceeds from issuance of long-term debt		0
Payments on long-term debt		0
Net payments under revolving credit facilities		0
Cash paid for dividends		0
Cash paid for employee taxes related to shares withheld		0
Principal payments on capital lease obligations		0
Net cash used in financing activities		0
Foreign exchange effect on cash and cash equivalents		0
Net decrease in cash and cash equivalents		0
Cash and cash equivalents, beginning of period		0
Cash and cash equivalents, end of period		$ 0
[1]	As Restated

Restatement of Previously Iss46

Restatement of Previously Issued Financial Statements - Restated Consolidated Statements of Cash Flows (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Accounting Changes and Error Corrections [Abstract]
Employee taxes related to shares withheld from operating activities to financing activities	$ 5,601	$ 1,410	[1]
[1]	As Restated

Merger Agreement - Additional I

Merger Agreement - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Apr. 13, 2017	Jan. 30, 2016	Mar. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Preferred Stock, par value			$ 0.001	$ 0.001
Merger Agreement [Member]
Business Acquisition [Line Items]
Right to receive cash by each common stockholder		$ 56
Termination fee of agreement		$ 177	$ 161
Merger Agreement [Member] | Conversion Shares Related to Series B Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Preferred Stock, par value		$ 0.001
Merger Agreement [Member] | Subsequent Events [Member]
Business Acquisition [Line Items]
Right to receive cash by each common stockholder	$ 51

Cash and Cash Equivalents - Add

Cash and Cash Equivalents - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017
Cash and Cash Equivalents [Abstract]
Cash investments maturity period	Three months or less

Inventories - Inventories are S

Inventories - Inventories are Stated at Lower of Cost (First In, First Out) or Market (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 103,838	$ 97,652
Work-in-process	68,471	69,086
Finished goods	150,164	142,182
Inventories, net	$ 322,473	$ 308,920

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 10,363	$ 9,602	[1]
Benefit for income taxes	493	0
Stock-based compensation, net of tax	10,856	9,602
Cost of Net Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	396	479
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense adjustment	384	398
Sales and Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	1,854	1,925
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 7,729	$ 6,800
[1]	As Restated

Net Loss Per Common Share - Com

Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Common Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	[1]
Numerator:
Loss from operations	$ (64,129)	$ (5,972)
Preferred stock dividends	(5,250)	(5,309)
Loss from operations attributable to common shares	(69,379)	(11,281)
Less: Net income attributable to non-controlling interest	183	103
Net income (loss) available to common stockholders	$ (69,562)	$ (11,384)
Denominator:
Weighted-average common shares outstanding - basic and diluted	87,221	86,646
Basic and diluted net loss per common share:
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries	$ (0.80)	$ (0.13)
[1]	As Restated

Net Loss Per Common Share - Pot

Net Loss Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Common Share (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	16,560	21,028
Options to Purchase Shares of Common Stock [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	6,322	7,378
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	0	3,411
Conversion Shares Related to Series B Convertible Preferred Stock [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	10,238	10,239

Net Loss Per Common Share - P53

Net Loss Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Common Share (Parenthetical) (Detail)	Mar. 31, 2017	Mar. 31, 2016
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Interest rate of debt instrument	3.00%	3.00%

Stockholders' Equity and Non-54

Stockholders' Equity and Non-Controlling Interests - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Class of Stock [Line Items]
Preferred stock dividends	$ 5,250,000	$ 5,309,000	[1]
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock dividends	5,300,000	5,300,000
Preferred stock dividends accrued	5,300,000
Preferred stock dividends cash paid	$ 5,300,000	$ 5,300,000
[1]	As Restated

Stockholders' Equity and Non-55

Stockholders' Equity and Non-Controlling Interests - Summary of Changes in Stockholders' Equity and Non-controlling Interests Comprising Total Equity (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	[1]
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period	$ 1,831,607
Issuance of common stock under employee compensation plans	424
Surrender of common stock to settle taxes on restricted stock units	(5,582)
Preferred stock dividends	(5,323)
Stock-based compensation expense	10,363
Other adjustments	4
Net income (loss)	(64,129)	$ (5,972)
Total other comprehensive income	53,259	$ 22,348
Equity, end of period	1,820,623
Total Stockholders' Equity [Member]
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period	1,826,992
Issuance of common stock under employee compensation plans	424
Surrender of common stock to settle taxes on restricted stock units	(5,582)
Preferred stock dividends	(5,323)
Stock-based compensation expense	10,363
Other adjustments	0
Net income (loss)	(64,312)
Total other comprehensive income	53,259
Equity, end of period	1,815,821
Non-controlling Interests [Member]
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period	4,615
Issuance of common stock under employee compensation plans	0
Surrender of common stock to settle taxes on restricted stock units	0
Preferred stock dividends	0
Stock-based compensation expense	0
Other adjustments	4
Net income (loss)	183
Total other comprehensive income	0
Equity, end of period	$ 4,802
[1]	As Restated

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Feb. 11, 2016
Business Acquisition [Line Items]
Goodwill	$ 2,781,100		$ 2,759,366
EDTS [Member]
Business Acquisition [Line Items]
Preliminary aggregate purchase price				$ 6,500
Total revenue related to acquisition	1,600	$ 900
Goodwill	$ 2,100

Business Combinations - Summary

Business Combinations - Summary of Aggregate Purchase Price Allocation (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Business Combinations [Abstract]
Current assets	$ 1,371
Property, plant and equipment	115
Goodwill	2,060
Intangible assets	4,220
Total assets acquired	7,766
Current liabilities	368
Non-current liabilities	928
Total liabilities assumed	1,296
Net assets acquired	6,470
Cash paid	$ 6,470

Business Combinations - Intangi

Business Combinations - Intangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Finite And Infinite Lived Intangible Assets [Line Items]
Total intangible assets	$ 4,220
Core Technology and Patents [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 540
Weighted-average Useful Life	10 years
Trademarks and Trade Names [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 310
Weighted-average Useful Life	20 years
Customer Relationships [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 2,800
Weighted-average Useful Life	14 years
Non-Compete Agreements [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 570
Weighted-average Useful Life	3 years

Restructuring - Aggregate Charg

Restructuring - Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 3,031	$ 7,668
Restructuring charges	3,031	7,668
Interest Expense, Including Amortization of Original Issue Discounts and Deferred Financing Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1	5
Cost of Net Revenue [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	815	1,267
Research and Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	127	1,920
Sales and Marketing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	10	650
General and Administrative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,078	3,826
Total Operating Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 3,030	$ 7,663

Restructuring - Restructuring A

Restructuring - Restructuring Activities Related to Restructuring Plans (Detail) - USD ($) $ in Thousands	3 Months Ended		111 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 3,031	$ 7,668
Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,122	4,688
Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,909	2,980
2016 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3,031	7,668	$ 124,927
2016 Restructuring Plans [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,122	4,688	85,424
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	678	3,091	48,101
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Facility and Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	443	981	16,378
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Other Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1	5	834
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Cash Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,122	4,077	65,313
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Fixed Asset and Inventory Impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	398	17,951
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Other Non-Cash Recoveries [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	213	2,160
2016 Restructuring Plans [Member] | Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,909	2,980	39,503
2016 Restructuring Plans [Member] | Corporate and Other [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1	15	4,624
2016 Restructuring Plans [Member] | Corporate and Other [Member] | Facility and Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 1,908	$ 2,965	$ 34,879

Restructuring - Additional Info

Restructuring - Additional Information (Detail) $ in Millions	Mar. 31, 2017USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring reserves included in accrued expenses and other current liabilities	$ 6.4
Restructuring reserves included in other long-term liabilities	0.3
2016 Restructuring Plans [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	12.9
2016 Restructuring Plans [Member] | Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	$ 2.3

Restructuring - Cash Activity f

Restructuring - Cash Activity for Restructuring Reserves (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Restructuring Cost and Reserve [Line Items]
Charges	$ 3,031	$ 7,668
Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	10,890
Charges	3,031
Payments	(7,249)
Currency adjustments	35
Restructuring Reserve, Ending Balance	6,707
Severance-Related Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	3,339
Charges	679
Payments	(766)
Currency adjustments	15
Restructuring Reserve, Ending Balance	3,267
Facility and Transition Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	7,512
Charges	2,351
Payments	(6,443)
Currency adjustments	20
Restructuring Reserve, Ending Balance	3,440
Other Exit Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	39
Charges	1
Payments	(40)
Currency adjustments	0
Restructuring Reserve, Ending Balance	$ 0

Long-Term Debt - Long-Term Debt

Long-Term Debt - Long-Term Debt Balances Outstanding (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Long-term debt, Total	$ 2,934,832	$ 2,940,575
Less: Short-term debt and current portion of long-term debt	(82,506)	(82,370)
Long-term debt	2,852,326	2,858,205
Revolver Facility [Member]
Debt Instrument [Line Items]
Long-term debt, Total	125,000	125,000
A Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	538,372	544,745
B Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	950,756	952,664
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	443,924	442,709
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	415,813	415,102
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	413,300	412,831
Other Lines of Credit [Member]
Debt Instrument [Line Items]
Long-term debt, Total	1,202	1,124
Other [Member]
Debt Instrument [Line Items]
Long-term debt, Total	$ 46,465	$ 46,400

Long-Term Debt - Long-Term De64

Long-Term Debt - Long-Term Debt Balances Outstanding (Parenthetical) (Detail) $ in Thousands	3 Months Ended			15 Months Ended
	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)		Jul. 01, 2018USD ($)	May 31, 2017Amendments	Apr. 30, 2017Amendments	Dec. 31, 2016
Debt Instrument [Line Items]
Description of default under credit agreement	(i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes due 2018, or the 7.25% senior notes, our 6.5% senior subordinated notes due 2020, or the 6.5% senior subordinated notes, our 6.375% senior subordinated notes due 2023, or the 6.375% senior subordinated notes, and our 3% convertible senior subordinated notes due 2016, or the 3% convertible senior subordinated notes, as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) on April 22, 2016, we entered into an amendment to the Credit Agreement and, on May 10, 2016, we obtained consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K for the year ended December 31, 2015, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and certain related deliverables in order to avoid events of default under the Credit Agreement and the indentures governing our notes. As discussed more fully in Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources,” in August 2016 we entered into a further amendment to the Credit Agreement with respect to our failure to timely file our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.
Repayment of long term debt	$ 10,158	$ 17,275	[1]
Subsequent Events [Member]
Debt Instrument [Line Items]
Number of amendments | Amendments					2	2
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	7.25%	7.25%					7.25%
Debt instrument, maturity date	Jul. 1, 2018
Percentage of aggregate principal amount to be sold	101.00%
7.25% Senior Notes [Member] | Scenario, Forecast [Member]
Debt Instrument [Line Items]
Repayment of long term debt				$ 450,000
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.50%	6.50%					6.50%
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.375%	6.375%					6.375%
[1]	As Restated

Long-Term Debt - Long-Term De65

Long-Term Debt - Long-Term Debt Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Debt Instrument [Line Items]
Long-term debt issuance cost	$ 43,183	$ 42,106	[1]
Secured Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	18,730	17,043
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	9,372	8,524
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	7,242	7,003
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	7,617	7,231
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	0	1,244
Other [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	$ 222	$ 1,061
[1]	As Restated

Long-Term Debt - Long-Term De66

Long-Term Debt - Long-Term Debt Interest Expense (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016
Debt Instrument [Line Items]
Amortization fee	$ 2.1
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	7.25%	7.25%	7.25%
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.375%	6.375%	6.375%
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.50%	6.50%	6.50%
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	3.00%		3.00%

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - USD ($)	Jun. 15, 2017	Jun. 08, 2017	Jun. 05, 2017	Jun. 02, 2017	May 31, 2017	May 08, 2017	Apr. 28, 2017	Apr. 24, 2017	Mar. 31, 2017	May 01, 2017
Debt Instrument [Line Items]
Third amendment consent fee, percentage of outstanding and credit commitment amount									0.125%
Fees and expenses associated with fourth amendment									$ 5,400,000
Subsequent Events [Member]
Debt Instrument [Line Items]
Fees and expenses associated with third amendment								$ 3,300,000
Consent aggregate payments per 1,000 principal amount		$ 7.50	$ 1			$ 10	$ 17.50
Trustee or holders obligation payment percentage of Notes				25.00%
Aggregate amount of consent termination fee		$ 1,300,000								$ 23,000,000
Scenario, Forecast [Member]
Debt Instrument [Line Items]
Consent aggregate payments per 1,000 principal amount	$ 5
Trustee or holders obligation payment percentage of Notes	25.00%
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Senior subordinated notes, interest rate									6.50%
6.5% Senior Subordinated Notes [Member] | Subsequent Events [Member]
Debt Instrument [Line Items]
Consent aggregate payments per 1,000 principal amount					$ 15
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Senior subordinated notes, interest rate									6.375%
6.375% Senior Subordinated Notes [Member] | Subsequent Events [Member]
Debt Instrument [Line Items]
Consent aggregate payments per 1,000 principal amount					20
7.250% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Senior subordinated notes, interest rate									7.25%
7.250% Senior Subordinated Notes [Member] | Subsequent Events [Member]
Debt Instrument [Line Items]
Consent aggregate payments per 1,000 principal amount					$ 12.50

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	$ 540	$ 76
Total assets	540	76
Liabilities:
Contingent consideration obligations	43,400	43,200
Total liabilities	43,400	43,200
Quoted Prices in Active Markets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	540	76
Total assets	540	76
Liabilities:
Contingent consideration obligations	0	0
Total liabilities	0	0
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	0	0
Total assets	0	0
Liabilities:
Contingent consideration obligations	0	0
Total liabilities	0	0
Unobservable Inputs (Level 3) [Member]
Liabilities:
Contingent consideration obligations	43,400	43,200
Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	0	0
Total assets	0	0
Liabilities:
Contingent consideration obligations	43,400	43,200
Total liabilities	$ 43,400	$ 43,200

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Contingent Consideration Obligations (Detail) - Unobservable Inputs (Level 3) [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent consideration obligations, Beginning balance	$ 43,200
Payments	(287)
Fair value adjustments	489
Foreign currency adjustments	(2)
Fair value of contingent consideration obligations, Ending balance	$ 43,400

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Billions	Mar. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Estimated fair value of long-term debt	$ 3	$ 2.9
Long-term debt, Total	$ 2.9	$ 2.9

Financial Information by Segm71

Financial Information by Segment - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015Segment
Segment Reporting [Abstract]
Number of operating segments	2

Financial Information by Segm72

Financial Information by Segment - Performance of Our Operating Segments Based on Revenue and Operating Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016		Dec. 31, 2016
Segment Reporting Information [Line Items]
Net revenue	$ 588,216	$ 586,940	[1]
Operating income (loss)	(5,022)	32,277	[1]
Depreciation and amortization	60,934	72,504	[1]
Restructuring charge	3,031	7,668
Stock-based compensation	10,363	9,602	[1]
Assets	5,673,869			$ 5,648,279
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	534,317	534,513
Operating income (loss)	88,957	80,356
Depreciation and amortization	54,289	63,673
Restructuring charge	1,122	4,688
Stock-based compensation	0	0
Assets	5,170,280			5,199,806
Consumer Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	17,240	17,442
Operating income (loss)	71	167
Depreciation and amortization	1,155	1,499
Restructuring charge	0	0
Stock-based compensation	0	0
Assets	177,686			175,362
Other Non-Reportable Segments [Member]
Segment Reporting Information [Line Items]
Net revenue	36,659	34,985
Operating income (loss)	6,616	6,238
Depreciation and amortization	3,188	5,159
Restructuring charge	0	0
Stock-based compensation	0	0
Assets	88,366			87,193
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net revenue	0	0
Operating income (loss)	(100,666)	(54,484)
Depreciation and amortization	2,302	2,173
Restructuring charge	1,909	2,980
Stock-based compensation	10,363	$ 9,602
Assets	$ 237,537			$ 185,918
[1]	As Restated

Financial Information by Segm73

Financial Information by Segment - Summary of Company's Net Revenue from Professional Diagnostics Reporting Segments by Groups of Similar Products and Services (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Sales revenue net	$ 585,574	$ 584,211	[1]
Total professional diagnostics net product sales and services revenue	122,129	115,709	[1]
License and royalty revenue	2,642	2,729	[1]
Net revenue	588,216	586,940	[1]
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	534,317	534,513
Reportable Subsegments [Member]
Segment Reporting Information [Line Items]
Total professional diagnostics net product sales and services revenue	531,675	531,784
License and royalty revenue	2,642	2,729
Net revenue	534,317	534,513
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Cardiometabolic [Member]
Segment Reporting Information [Line Items]
Sales revenue net	125,176	159,663
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Infectious Disease [Member]
Segment Reporting Information [Line Items]
Sales revenue net	222,934	191,956
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Toxicology [Member]
Segment Reporting Information [Line Items]
Sales revenue net	150,637	146,783
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Other [Member]
Segment Reporting Information [Line Items]
Sales revenue net	$ 32,928	$ 33,382
[1]	As Restated

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Mar. 31, 2017CNY (¥)	Sep. 16, 2016	May 31, 2007
Related Party Transaction [Line Items]
Restructuring charges	$ 3,031	$ 7,668
SPD [Member]
Related Party Transaction [Line Items]
Equity method investment ownership percentage	50.00%		50.00%		50.00%		50.00%
SPD Shanghai [Member]
Related Party Transaction [Line Items]
Restricted cash	$ 3,300		$ 3,300
SPD Shanghai [Member] | Alere Shanghai [Member]
Related Party Transaction [Line Items]
Loan arrangement from related party	3,300		3,300
SPD Shanghai [Member] | Maximum [Member] | Alere Shanghai [Member]
Related Party Transaction [Line Items]
Loan arrangement from related party | ¥					¥ 23,000,000
TechLab [Member]
Related Party Transaction [Line Items]
Percentage of equity method investments sold						49.00%
Purchases from related party		4,600
SPD Joint Venture [Member]
Related Party Transaction [Line Items]
Net payable to SPD	4,700		4,700	$ 3,700
Restructuring charges			1,200	1,200
Long-term receivable cost related to restructuring plan	6,200		6,200	6,100
Customer receivables associated with revenue earned after SPD was completed have been classified as other receivables	8,200		$ 8,200	$ 7,500
SPD Joint Venture [Member] | Sales Revenue Goods [Member]
Related Party Transaction [Line Items]
Revenue from joint venture	18,100	17,700
SPD Joint Venture [Member] | Sales Revenue Services [Member]
Related Party Transaction [Line Items]
Revenue from joint venture	$ 300	$ 200

Related Party Transactions - Re

Related Party Transactions - Related Party Balances with SPD within Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	$ 387,687	$ 413,535
Prepaid expenses and other current assets	117,828	118,607
Other non-current assets	14,340	14,966
Accounts payable	211,430	195,879
SPD Joint Venture [Member]
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	7,104	7,855
Prepaid expenses and other current assets	8,231	7,486
Other non-current assets	6,228	6,122
Accounts payable	$ 32,413	$ 34,216

Commitments and Contingencies -

Commitments and Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Business Acquisition, Contingent Consideration [Line Items]
Estimated Fair Value	$ 43,400,000	$ 43,200,000
Payments Made During 2017	$ 287,000
TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Mar. 11, 2010
Acquisition Date Fair Value	$ 35,600,000
Maximum Remaining Earn-out Potential	102,535,000
Estimated Fair Value	36,300,000	35,700,000
Payments Made During 2017	$ 159,000
Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Feb. 1, 2013
Acquisition Date Fair Value	$ 75,000,000
Maximum Remaining Earn-out Potential	15,375,000
Estimated Fair Value	3,000,000	3,000,000
Payments Made During 2017	$ 0
Other [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Various
Acquisition Date Fair Value	$ 30,373,000
Maximum Remaining Earn-out Potential	0
Estimated Fair Value	4,100,000	$ 4,500,000
Payments Made During 2017	$ 128,000
Minimum [Member] | TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,017
Minimum [Member] | Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,017
Maximum [Member] | TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,025
Maximum [Member] | Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,018

Commitments and Contingencies77

Commitments and Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Earn-out period	15 years

Commitments and Contingencies78

Commitments and Contingencies - Additional Information (Detail)	Oct. 12, 2016USD ($)Patient	Mar. 31, 2017USD ($)	May 31, 2017USD ($)
Loss Contingencies [Line Items]
Number of Medicare beneficiaries deceased | Patient	211
Medicare claims	$ 5,700,000
Number of Medicare beneficiaries | Patient	1,000,000
Loss Contingency Accrual		$ 35,000,000
Subsequent Events [Member] | Ionian Technologies, Inc. [Member]
Loss Contingencies [Line Items]
Earn-out payments under the agreement owed			$ 30,000,000
Original Merger Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Payment to be received upon termination of merger agreement		30,000,000
Original Merger Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Payment to be received upon termination of merger agreement		$ 50,000,000

Recent Accounting Pronounceme79

Recent Accounting Pronouncements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Provision (benefit) for income taxes	$ 18,609	$ (172)	[1]
Cash paid for employee taxes related to shares withheld	5,601	1,410	[1]
ASU No. 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Provision (benefit) for income taxes	$ (100)
Cash paid for employee taxes related to shares withheld		$ 1,400
[1]	As Restated

Equity Investments - Additional

Equity Investments - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 16, 2016	Mar. 31, 2017	Mar. 31, 2016		May 31, 2007
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax		$ 5,201	$ 5,034	[1]
SPD [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax		$ 5,000	4,600
Equity method investment ownership percentage		50.00%			50.00%
TechLab [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax		$ 200	$ 500
Percentage of equity method investments sold	49.00%
Gain (Loss) on sale of equity method investment, before tax	$ 29,900
[1]	As Restated

Equity Investments - Financial

Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Results of Operations (Detail) - TechLab [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Schedule of Equity Method Investments [Line Items]
Net revenue	$ 45,392	$ 53,434
Gross profit	35,133	36,219
Net income after taxes	$ 10,048	$ 10,141

Equity Investments - Financia82

Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Balance Sheet (Detail) - Equity Method Investee [Member] - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Schedule of Equity Method Investments [Line Items]
Current assets	$ 85,888	$ 75,248
Non-current assets	21,246	20,578
Total assets	107,134	95,826
Current liabilities	43,890	44,234
Non-current liabilities	3,945	3,875
Total liabilities	$ 47,835	$ 48,109

Impairment and (Gain) Loss on83

Impairment and (Gain) Loss on Dispositions, Net - Additional Information (Detail) - Alere E-Sante [Member] - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Jan. 31, 2016	Mar. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale of business, cash received	$ 8.1
Sale of business, working capital adjustment	0.2
Sale of business, contingent consideration	$ 1.5
Gain (Loss) on sale of disposal group		$ 3.8

Provision (Benefit) for Incom84

Provision (Benefit) for Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Provision for income taxes increased	$ 18,800,000
Provision (benefit) for income taxes	$ 18,609,000	$ (172,000)	[1]
Effective tax rate	(37.00%)	2.00%
Valuation allowance	$ 0
[1]	As Restated

Guarantor Financial Informati85

Guarantor Financial Information - Additional Information (Detail)	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	7.25%	7.25%	7.25%
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	6.50%	6.50%	6.50%
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	6.375%	6.375%	6.375%

Guarantor Financial Informati86

Guarantor Financial Information - Consolidating Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Condensed Financial Statements, Captions [Line Items]
Net product sales	$ 463,445	$ 468,502	[1]
Services revenue	122,129	115,709	[1]
Net product sales and services revenue	585,574	584,211	[1]
License and royalty revenue	2,642	2,729	[1]
Net revenue	588,216	586,940	[1]
Cost of net product sales	229,831	241,324	[1]
Cost of services revenue	75,899	73,100	[1]
Cost of net product sales and services revenue	305,730	314,424	[1]
Cost of license and royalty revenue	760	1,391	[1]
Cost of net revenue	306,490	315,815	[1]
Gross profit (loss)	281,726	271,125	[1]
Operating expenses:
Research and development	26,284	27,062	[1]
Sales and marketing	94,191	100,640	[1]
General and administrative	166,273	114,956	[1]
Impairment and (gain) loss on dispositions, net	0	(3,810)	[1]
Operating (loss) income	(5,022)	32,277	[1]
Interest expense, including amortization of original issue discounts and deferred financing costs	(43,183)	(42,106)	[1]
Other income (expense), net	(2,516)	(1,349)	[1]
Income (loss) before provision (benefit) for income taxes	(50,721)	(11,178)	[1]
Provision (benefit) for income taxes	18,609	(172)	[1]
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	(69,330)	(11,006)
Equity in earnings of subsidiaries, net of tax	0	0
Equity earnings of unconsolidated entities, net of tax	5,201	5,034	[1]
Net income (loss)	(64,129)	(5,972)	[1]
Less: Net income attributable to non-controlling interests	183	103	[1]
Net income (loss) attributable to Alere Inc. and Subsidiaries	(64,312)	(6,075)	[1]
Preferred stock dividends	(5,250)	(5,309)	[1]
Net income (loss) available to common stockholders	(69,562)	(11,384)	[1]
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	0	0
Services revenue	0	0
Net product sales and services revenue	0	0
License and royalty revenue	0	0
Net revenue	0	0
Cost of net product sales	1,139	114
Cost of services revenue	45	0
Cost of net product sales and services revenue	1,184	114
Cost of license and royalty revenue	0	0
Cost of net revenue	1,184	114
Gross profit (loss)	(1,184)	(114)
Operating expenses:
Research and development	1,220	4,134
Sales and marketing	1,925	1,336
General and administrative	94,300	44,615
Impairment and (gain) loss on dispositions, net	0	0
Operating (loss) income	(98,629)	(50,199)
Interest expense, including amortization of original issue discounts and deferred financing costs	(42,961)	(41,087)
Other income (expense), net	2,577	1,988
Income (loss) before provision (benefit) for income taxes	(139,013)	(89,298)
Provision (benefit) for income taxes	13,547	(54)
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	(152,560)	(89,244)
Equity in earnings of subsidiaries, net of tax	88,202	82,591
Equity earnings of unconsolidated entities, net of tax	229	681
Net income (loss)	(64,129)	(5,972)
Less: Net income attributable to non-controlling interests	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	(64,129)	(5,972)
Preferred stock dividends	(5,250)	(5,309)
Net income (loss) available to common stockholders	(69,379)	(11,281)
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	263,294	224,380
Services revenue	109,531	104,484
Net product sales and services revenue	372,825	328,864
License and royalty revenue	3,730	2,920
Net revenue	376,555	331,784
Cost of net product sales	131,757	124,758
Cost of services revenue	76,484	72,495
Cost of net product sales and services revenue	208,241	197,253
Cost of license and royalty revenue	0	17
Cost of net revenue	208,241	197,270
Gross profit (loss)	168,314	134,514
Operating expenses:
Research and development	17,890	14,459
Sales and marketing	48,344	54,465
General and administrative	34,522	33,186
Impairment and (gain) loss on dispositions, net	0	0
Operating (loss) income	67,558	32,404
Interest expense, including amortization of original issue discounts and deferred financing costs	(1,877)	(2,652)
Other income (expense), net	1,552	2,502
Income (loss) before provision (benefit) for income taxes	67,233	32,254
Provision (benefit) for income taxes	0	250
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	67,233	32,004
Equity in earnings of subsidiaries, net of tax	0	0
Equity earnings of unconsolidated entities, net of tax	0	0
Net income (loss)	67,233	32,004
Less: Net income attributable to non-controlling interests	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	67,233	32,004
Preferred stock dividends	0	0
Net income (loss) available to common stockholders	67,233	32,004
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	272,910	305,568
Services revenue	12,598	11,225
Net product sales and services revenue	285,508	316,793
License and royalty revenue	854	2,558
Net revenue	286,362	319,351
Cost of net product sales	161,862	169,845
Cost of services revenue	7,588	8,040
Cost of net product sales and services revenue	169,450	177,885
Cost of license and royalty revenue	2,702	4,123
Cost of net revenue	172,152	182,008
Gross profit (loss)	114,210	137,343
Operating expenses:
Research and development	7,174	8,469
Sales and marketing	43,922	44,839
General and administrative	37,764	37,155
Impairment and (gain) loss on dispositions, net	0	(3,810)
Operating (loss) income	25,350	50,690
Interest expense, including amortization of original issue discounts and deferred financing costs	(2,278)	(3,067)
Other income (expense), net	(2,711)	(1,139)
Income (loss) before provision (benefit) for income taxes	20,361	46,484
Provision (benefit) for income taxes	5,062	(368)
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	15,299	46,852
Equity in earnings of subsidiaries, net of tax	0	0
Equity earnings of unconsolidated entities, net of tax	4,972	4,581
Net income (loss)	20,271	51,433
Less: Net income attributable to non-controlling interests	183	103
Net income (loss) attributable to Alere Inc. and Subsidiaries	20,088	51,330
Preferred stock dividends	0	0
Net income (loss) available to common stockholders	20,088	51,330
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	(72,759)	(61,446)
Services revenue	0	0
Net product sales and services revenue	(72,759)	(61,446)
License and royalty revenue	(1,942)	(2,749)
Net revenue	(74,701)	(64,195)
Cost of net product sales	(64,927)	(53,393)
Cost of services revenue	(8,218)	(7,435)
Cost of net product sales and services revenue	(73,145)	(60,828)
Cost of license and royalty revenue	(1,942)	(2,749)
Cost of net revenue	(75,087)	(63,577)
Gross profit (loss)	386	(618)
Operating expenses:
Research and development	0	0
Sales and marketing	0	0
General and administrative	(313)	0
Impairment and (gain) loss on dispositions, net	0	0
Operating (loss) income	699	(618)
Interest expense, including amortization of original issue discounts and deferred financing costs	3,933	4,700
Other income (expense), net	(3,934)	(4,700)
Income (loss) before provision (benefit) for income taxes	698	(618)
Provision (benefit) for income taxes	0	0
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	698	(618)
Equity in earnings of subsidiaries, net of tax	(88,202)	(82,591)
Equity earnings of unconsolidated entities, net of tax	0	(228)
Net income (loss)	(87,504)	(83,437)
Less: Net income attributable to non-controlling interests	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	(87,504)	(83,437)
Preferred stock dividends	0	0
Net income (loss) available to common stockholders	$ (87,504)	$ (83,437)
[1]	As Restated

Guarantor Financial Informati87

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	$ (64,129)	$ (5,972)	[1]
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	53,330	22,193	[1]
Minimum pension liability adjustment	(71)	155	[1]
Other comprehensive income (loss), before tax	53,259	22,348	[1]
Other comprehensive income (loss)	53,259	22,348	[1]
Comprehensive income (loss)	(10,870)	16,376	[1]
Less: Comprehensive income attributable to non-controlling interests	183	103	[1]
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	(11,053)	16,273	[1]
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	(64,129)	(5,972)
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	27	115
Other comprehensive income (loss), before tax	27	115
Other comprehensive income (loss)	27	115
Comprehensive income (loss)	(64,102)	(5,857)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	(64,102)	(5,857)
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	67,233	32,004
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	164	(129)
Other comprehensive income (loss), before tax	164	(129)
Other comprehensive income (loss)	164	(129)
Comprehensive income (loss)	67,397	31,875
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	67,397	31,875
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	20,271	51,433
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	53,180	22,207
Minimum pension liability adjustment	(71)	155
Other comprehensive income (loss), before tax	53,109	22,362
Other comprehensive income (loss)	53,109	22,362
Comprehensive income (loss)	73,380	73,795
Less: Comprehensive income attributable to non-controlling interests	183	103
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	73,197	73,692
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	(87,504)	(83,437)
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(41)
Other comprehensive income (loss), before tax	(41)
Other comprehensive income (loss)	(41)
Comprehensive income (loss)	(87,545)	(83,437)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ (87,545)	$ (83,437)
[1]	As Restated

Guarantor Financial Informati88

Guarantor Financial Information - Consolidating Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 601,472	$ 567,215	$ 502,200	[1]
Restricted cash	53,143	51,550
Marketable securities	540	76
Accounts receivable, net of allowances	387,687	413,535
Inventories, net	322,473	308,920
Prepaid expenses and other current assets	117,828	118,607
Intercompany receivables	0	0
Total current assets	1,483,143	1,459,903
Property, plant and equipment, net	439,802	441,190
Goodwill	2,781,100	2,759,366
Other intangible assets with indefinite lives	22,118	27,164
Finite-lived intangible assets, net	785,065	805,577
Restricted cash	2,355	2,171
Other non-current assets	14,340	14,966
Investments in subsidiaries	0	0
Investments in unconsolidated entities	79,227	72,225
Deferred tax assets	22,475	20,483
Non-current income tax receivable	44,244	45,234
Intercompany notes receivables	0	0
Total assets	5,673,869	5,648,279
Current liabilities:
Short-term debt and current portion of long-term debt	82,506	82,370
Current portion of capital lease obligations	2,901	3,064
Accounts payable	211,430	195,879
Accrued expenses and other current liabilities	416,447	394,843
Intercompany payables	0	0
Total current liabilities	713,284	676,156
Long-term liabilities:
Long-term debt, net of current portion	2,852,326	2,858,205
Capital lease obligations, net of current portion	6,674	7,221
Deferred tax liabilities	120,826	119,098
Other long-term liabilities	160,136	155,992
Intercompany notes payables	0	0
Total long-term liabilities	3,139,962	3,140,516
Total stockholders' equity	1,815,821	1,826,992
Non-controlling interests	4,802	4,615
Total equity	1,820,623	1,831,607
Total liabilities and equity	5,673,869	5,648,279
Issuer [Member]
Current assets:
Cash and cash equivalents	215,718	167,639	139,153
Restricted cash	814	1,337
Marketable securities	0	0
Accounts receivable, net of allowances	0	0
Inventories, net	0	0
Prepaid expenses and other current assets	21,817	15,983
Intercompany receivables	383,305	390,328
Total current assets	621,654	575,287
Property, plant and equipment, net	23,061	25,525
Goodwill	0	0
Other intangible assets with indefinite lives	0	0
Finite-lived intangible assets, net	2,362	2,490
Restricted cash	0	0
Other non-current assets	463	509
Investments in subsidiaries	3,554,484	3,409,001
Investments in unconsolidated entities	875	684
Deferred tax assets	0	0
Non-current income tax receivable	4,580	4,580
Intercompany notes receivables	1,677,641	1,757,723
Total assets	5,885,120	5,775,799
Current liabilities:
Short-term debt and current portion of long-term debt	40,073	40,072
Current portion of capital lease obligations	0	0
Accounts payable	56,545	35,591
Accrued expenses and other current liabilities	146,351	65,582
Intercompany payables	505,213	485,573
Total current liabilities	748,182	626,818
Long-term liabilities:
Long-term debt, net of current portion	2,847,092	2,852,978
Capital lease obligations, net of current portion	0	0
Deferred tax liabilities	0	0
Other long-term liabilities	94,324	91,042
Intercompany notes payables	379,701	377,969
Total long-term liabilities	3,321,117	3,321,989
Total stockholders' equity	1,815,821	1,826,992
Non-controlling interests	0	0
Total equity	1,815,821	1,826,992
Total liabilities and equity	5,885,120	5,775,799
Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	4,168	3,161	21,150
Restricted cash	0	0
Marketable securities	83	76
Accounts receivable, net of allowances	182,775	186,067
Inventories, net	162,740	168,736
Prepaid expenses and other current assets	23,570	22,318
Intercompany receivables	1,106,663	1,008,767
Total current assets	1,479,999	1,389,125
Property, plant and equipment, net	241,058	243,755
Goodwill	1,823,446	1,822,290
Other intangible assets with indefinite lives	7,472	7,457
Finite-lived intangible assets, net	487,478	507,060
Restricted cash	0	0
Other non-current assets	1,739	2,267
Investments in subsidiaries	158,631	158,195
Investments in unconsolidated entities	14,765	14,765
Deferred tax assets	0	0
Non-current income tax receivable	0	0
Intercompany notes receivables	633,767	709,965
Total assets	4,848,355	4,854,879
Current liabilities:
Short-term debt and current portion of long-term debt	4	0
Current portion of capital lease obligations	1,433	1,560
Accounts payable	77,416	78,981
Accrued expenses and other current liabilities	133,109	133,506
Intercompany payables	860,907	859,924
Total current liabilities	1,072,869	1,073,971
Long-term liabilities:
Long-term debt, net of current portion	0	0
Capital lease obligations, net of current portion	1,732	2,029
Deferred tax liabilities	61,928	51,314
Other long-term liabilities	44,941	44,563
Intercompany notes payables	1,188,611	1,274,419
Total long-term liabilities	1,297,212	1,372,325
Total stockholders' equity	2,478,274	2,408,583
Non-controlling interests	0	0
Total equity	2,478,274	2,408,583
Total liabilities and equity	4,848,355	4,854,879
Non-Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	381,586	396,415	341,897
Restricted cash	52,329	50,213
Marketable securities	457	0
Accounts receivable, net of allowances	204,912	227,468
Inventories, net	183,813	163,967
Prepaid expenses and other current assets	67,839	68,748
Intercompany receivables	110,136	204,587
Total current assets	1,001,072	1,111,398
Property, plant and equipment, net	180,798	176,618
Goodwill	957,654	937,076
Other intangible assets with indefinite lives	14,705	19,765
Finite-lived intangible assets, net	298,425	299,227
Restricted cash	2,355	2,171
Other non-current assets	12,946	13,060
Investments in subsidiaries	57,651	57,650
Investments in unconsolidated entities	47,932	42,523
Deferred tax assets	59,811	57,819
Non-current income tax receivable	39,664	40,654
Intercompany notes receivables	3,000	744
Total assets	2,676,013	2,758,705
Current liabilities:
Short-term debt and current portion of long-term debt	42,429	42,298
Current portion of capital lease obligations	1,468	1,504
Accounts payable	77,469	81,307
Accrued expenses and other current liabilities	171,964	223,778
Intercompany payables	233,912	258,154
Total current liabilities	527,242	607,041
Long-term liabilities:
Long-term debt, net of current portion	5,234	5,227
Capital lease obligations, net of current portion	4,942	5,192
Deferred tax liabilities	58,817	67,702
Other long-term liabilities	21,679	21,257
Intercompany notes payables	746,096	816,044
Total long-term liabilities	836,768	915,422
Total stockholders' equity	1,307,201	1,231,627
Non-controlling interests	4,802	4,615
Total equity	1,312,003	1,236,242
Total liabilities and equity	2,676,013	2,758,705
Eliminations [Member]
Current assets:
Cash and cash equivalents	0	0	$ 0
Restricted cash	0	0
Marketable securities	0	0
Accounts receivable, net of allowances	0	0
Inventories, net	(24,080)	(23,783)
Prepaid expenses and other current assets	4,602	11,558
Intercompany receivables	(1,600,104)	(1,603,682)
Total current assets	(1,619,582)	(1,615,907)
Property, plant and equipment, net	(5,115)	(4,708)
Goodwill	0	0
Other intangible assets with indefinite lives	(59)	(58)
Finite-lived intangible assets, net	(3,200)	(3,200)
Restricted cash		0
Other non-current assets	(808)	(870)
Investments in subsidiaries	(3,770,766)	(3,624,846)
Investments in unconsolidated entities	15,655	14,253
Deferred tax assets	(37,336)	(37,336)
Non-current income tax receivable	0	0
Intercompany notes receivables	(2,314,408)	(2,468,432)
Total assets	(7,735,619)	(7,741,104)
Current liabilities:
Short-term debt and current portion of long-term debt	0	0
Current portion of capital lease obligations	0	0
Accounts payable	0	0
Accrued expenses and other current liabilities	(34,977)	(28,023)
Intercompany payables	(1,600,032)	(1,603,651)
Total current liabilities	(1,635,009)	(1,631,674)
Long-term liabilities:
Long-term debt, net of current portion	0	0
Capital lease obligations, net of current portion	0	0
Deferred tax liabilities	81	82
Other long-term liabilities	(808)	(870)
Intercompany notes payables	(2,314,408)	(2,468,432)
Total long-term liabilities	(2,315,135)	(2,469,220)
Total stockholders' equity	(3,785,475)	(3,640,210)
Non-controlling interests	0	0
Total equity	(3,785,475)	(3,640,210)
Total liabilities and equity	$ (7,735,619)	$ (7,741,104)
[1]	As Restated

Guarantor Financial Informati89

Guarantor Financial Information - Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended			15 Months Ended
	Mar. 31, 2017	Mar. 31, 2016		Jul. 01, 2018
Cash Flows from Operating Activities:
Net income (loss)	$ (64,129)	$ (5,972)	[1]
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	0	0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	4,281	2,236	[1]
Depreciation and amortization	60,934	72,504	[1]
Non-cash stock-based compensation expense	10,363	9,602	[1]
Impairment of inventory	0	1,349	[1]
Impairment of long-lived assets	(342)	608	[1]
Loss on sale of fixed assets	2,341	323	[1]
Equity earnings of unconsolidated entities, net of tax	(5,201)	(5,034)	[1]
Deferred income taxes	(3,377)	(6,812)	[1]
Gain on business dispositions	0	(3,810)	[1]
Other non-cash items	1,564	2,496	[1]
Non-cash change in fair value of contingent consideration	489	142	[1]
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	33,105	(17,930)	[1]
Inventories, net	(19,272)	(10,284)	[1]
Prepaid expenses and other current assets	3,750	(5,775)	[1]
Accounts payable	13,363	(31,542)	[1]
Accrued expenses and other current liabilities	17,714	(5,182)	[1]
Other non-current assets and liabilities	5,652	35	[1]
Cash paid for contingent consideration	(159)	(143)	[1]
Intercompany payable (receivable)	0	0
Net cash (used in) provided by operating activities	61,076	(3,189)	[1]
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash	(1,445)	(436)	[1]
Purchases of property, plant and equipment	(10,399)	(14,504)	[1]
Proceeds from sale of property, plant and equipment	139	612	[1]
Cash received from (used in) business dispositions, net of cash divested	0	21,470	[1]
Cash paid for business acquisitions, net of cash acquired	(3,060)	(5,945)	[1]
Cash received from sales of marketable securities	(7)	93	[1]
Cash received from equity method investments	0	2,205	[1]
Cash paid for equity investments	(232)	(184)	[1]
Proceeds from sale of equity investments	229	0	[1]
Decrease (Increase) in other assets	82	(540)	[1]
Net cash (used in) provided by investing activities	(14,693)	2,771	[1]
Cash Flows from Financing Activities:
Cash paid for financing costs	0	(1)	[1]
Cash paid for contingent consideration	(128)	(145)	[1]
Proceeds from issuance of common stock, net of issuance costs	496	11,124	[1]
Proceeds from issuance of long-term debt	0	325	[1]
Payments on long-term debt	(10,158)	(17,275)	[1]
Net proceeds (payments) under revolving credit facilities	48	(127)	[1]
Cash paid for dividends	(5,323)	(5,323)	[1]
Cash paid for employee taxes related to shares withheld	(5,601)	(1,410)	[1]
Principal payments on capital lease obligations	(852)	(1,107)	[1]
Net cash used in financing activities	(21,518)	(13,939)	[1]
Foreign exchange effect on cash and cash equivalents	9,392	2,820	[1]
Net increase (decrease) in cash and cash equivalents	34,257	(11,537)	[1]
Cash and cash equivalents, beginning of period	567,215	502,200	[1]	$ 601,472
Cash and cash equivalents, end of period	601,472	490,663	[1]
Issuer [Member]
Cash Flows from Operating Activities:
Net income (loss)	(64,129)	(5,972)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	(88,202)	(82,591)
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	4,251	2,188
Depreciation and amortization	2,390	2,203
Non-cash stock-based compensation expense	6,241	5,069
Impairment of inventory		0
Impairment of long-lived assets	0	0
Loss on sale of fixed assets	0	15
Equity earnings of unconsolidated entities, net of tax	(229)	(681)
Deferred income taxes	2,252	0
Gain on business dispositions		0
Other non-cash items	286	105
Non-cash change in fair value of contingent consideration	0	(1,000)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	0	0
Inventories, net	0	0
Prepaid expenses and other current assets	(5,982)	(1,137)
Accounts payable	21,415	(3,694)
Accrued expenses and other current liabilities	78,365	10,584
Other non-current assets and liabilities	921	157,791
Cash paid for contingent consideration	0	(143)
Intercompany payable (receivable)	111,553	(111,564)
Net cash (used in) provided by operating activities	69,132	(28,827)
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash	523	(513)
Purchases of property, plant and equipment	(624)	(841)
Proceeds from sale of property, plant and equipment	0	0
Cash received from (used in) business dispositions, net of cash divested		(1,337)
Cash paid for business acquisitions, net of cash acquired	(3,100)	0
Cash received from sales of marketable securities	0	0
Cash received from equity method investments		2,205
Cash paid for equity investments	(191)	(184)
Proceeds from sale of equity investments	229
Decrease (Increase) in other assets	47	(64)
Net cash (used in) provided by investing activities	(3,116)	(734)
Cash Flows from Financing Activities:
Cash paid for financing costs		(1)
Cash paid for contingent consideration	0	0
Proceeds from issuance of common stock, net of issuance costs	496	11,124
Proceeds from issuance of long-term debt		0
Payments on long-term debt	(10,018)	(17,030)
Net proceeds (payments) under revolving credit facilities	0	0
Cash paid for dividends	(5,323)	(5,323)
Cash paid for employee taxes related to shares withheld	(3,092)	(1,291)
Principal payments on capital lease obligations	0	0
Net cash used in financing activities	(17,937)	(12,521)
Foreign exchange effect on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	48,079	(42,082)
Cash and cash equivalents, beginning of period	167,639	139,153		215,718
Cash and cash equivalents, end of period	215,718	97,071
Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income (loss)	67,233	32,004
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	0	0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	1	4
Depreciation and amortization	37,398	45,691
Non-cash stock-based compensation expense	1,857	2,287
Impairment of inventory		0
Impairment of long-lived assets	(342)	608
Loss on sale of fixed assets	2,222	8
Equity earnings of unconsolidated entities, net of tax	0	0
Deferred income taxes	0	(100)
Gain on business dispositions		0
Other non-cash items	102	303
Non-cash change in fair value of contingent consideration	759	1,199
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	3,815	(7,875)
Inventories, net	(3,207)	(6,681)
Prepaid expenses and other current assets	(1,409)	1,514
Accounts payable	(1,170)	(6,773)
Accrued expenses and other current liabilities	494	(94,355)
Other non-current assets and liabilities	9,665	(159,277)
Cash paid for contingent consideration	(159)	0
Intercompany payable (receivable)	(109,644)	180,953
Net cash (used in) provided by operating activities	7,615	(10,490)
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash	0	0
Purchases of property, plant and equipment	(5,143)	(5,615)
Proceeds from sale of property, plant and equipment	3	40
Cash received from (used in) business dispositions, net of cash divested		0
Cash paid for business acquisitions, net of cash acquired	40	0
Cash received from sales of marketable securities	(7)	93
Cash received from equity method investments		0
Cash paid for equity investments	0	0
Proceeds from sale of equity investments	0
Decrease (Increase) in other assets	4	(98)
Net cash (used in) provided by investing activities	(5,103)	(5,580)
Cash Flows from Financing Activities:
Cash paid for financing costs		0
Cash paid for contingent consideration	0	0
Proceeds from issuance of common stock, net of issuance costs	0	0
Proceeds from issuance of long-term debt		0
Payments on long-term debt	0	0
Net proceeds (payments) under revolving credit facilities	0	0
Cash paid for dividends	0	0
Cash paid for employee taxes related to shares withheld	(1,095)	(99)
Principal payments on capital lease obligations	(424)	(659)
Net cash used in financing activities	(1,519)	(758)
Foreign exchange effect on cash and cash equivalents	14	160
Net increase (decrease) in cash and cash equivalents	1,007	(16,668)
Cash and cash equivalents, beginning of period	3,161	21,150		4,168
Cash and cash equivalents, end of period	4,168	4,482
Non-Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income (loss)	20,271	51,433
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	0	0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	29	44
Depreciation and amortization	21,384	23,722
Non-cash stock-based compensation expense	2,265	2,246
Impairment of inventory		1,349
Impairment of long-lived assets	0	0
Loss on sale of fixed assets	119	300
Equity earnings of unconsolidated entities, net of tax	(4,972)	(4,581)
Deferred income taxes	(5,629)	(6,712)
Gain on business dispositions		(3,810)
Other non-cash items	1,172	2,088
Non-cash change in fair value of contingent consideration	(270)	(57)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	29,290	(10,055)
Inventories, net	(15,605)	(3,333)
Prepaid expenses and other current assets	4,186	(6,177)
Accounts payable	(6,882)	(21,075)
Accrued expenses and other current liabilities	(54,191)	78,614
Other non-current assets and liabilities	(4,934)	1,583
Cash paid for contingent consideration	0	0
Intercompany payable (receivable)	(2,158)	(69,389)
Net cash (used in) provided by operating activities	(15,925)	36,190
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash	(1,968)	77
Purchases of property, plant and equipment	(4,942)	(8,048)
Proceeds from sale of property, plant and equipment	446	572
Cash received from (used in) business dispositions, net of cash divested		22,807
Cash paid for business acquisitions, net of cash acquired	0	(5,945)
Cash received from sales of marketable securities	0	0
Cash received from equity method investments		0
Cash paid for equity investments	(41)	0
Proceeds from sale of equity investments	0
Decrease (Increase) in other assets	31	(440)
Net cash (used in) provided by investing activities	(6,474)	9,023
Cash Flows from Financing Activities:
Cash paid for financing costs		0
Cash paid for contingent consideration	(128)	(145)
Proceeds from issuance of common stock, net of issuance costs	0	0
Proceeds from issuance of long-term debt		325
Payments on long-term debt	(140)	(245)
Net proceeds (payments) under revolving credit facilities	48	(127)
Cash paid for dividends	0	0
Cash paid for employee taxes related to shares withheld	(1,414)	(20)
Principal payments on capital lease obligations	(428)	(448)
Net cash used in financing activities	(2,062)	(660)
Foreign exchange effect on cash and cash equivalents	9,632	2,660
Net increase (decrease) in cash and cash equivalents	(14,829)	47,213
Cash and cash equivalents, beginning of period	396,415	341,897		381,586
Cash and cash equivalents, end of period	381,586	389,110
Eliminations [Member]
Cash Flows from Operating Activities:
Net income (loss)	(87,504)	(83,437)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	88,202	82,591
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	0	0
Depreciation and amortization	(238)	888
Non-cash stock-based compensation expense	0	0
Impairment of inventory		0
Impairment of long-lived assets	0	0
Loss on sale of fixed assets	0	0
Equity earnings of unconsolidated entities, net of tax	0	228
Deferred income taxes	0	0
Gain on business dispositions		0
Other non-cash items	4	0
Non-cash change in fair value of contingent consideration	0	0
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	0	0
Inventories, net	(460)	(270)
Prepaid expenses and other current assets	6,955	25
Accounts payable	0	0
Accrued expenses and other current liabilities	(6,954)	(25)
Other non-current assets and liabilities	0	(62)
Cash paid for contingent consideration	0	0
Intercompany payable (receivable)	249	0
Net cash (used in) provided by operating activities	254	(62)
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash	0	0
Purchases of property, plant and equipment	310	0
Proceeds from sale of property, plant and equipment	(310)	0
Cash received from (used in) business dispositions, net of cash divested		0
Cash paid for business acquisitions, net of cash acquired	0	0
Cash received from sales of marketable securities	0	0
Cash received from equity method investments		0
Cash paid for equity investments	0	0
Proceeds from sale of equity investments	0
Decrease (Increase) in other assets	0	62
Net cash (used in) provided by investing activities	0	62
Cash Flows from Financing Activities:
Cash paid for financing costs		0
Cash paid for contingent consideration	0	0
Proceeds from issuance of common stock, net of issuance costs	0	0
Proceeds from issuance of long-term debt		0
Payments on long-term debt	0	0
Net proceeds (payments) under revolving credit facilities	0	0
Cash paid for dividends	0	0
Cash paid for employee taxes related to shares withheld	0	0
Principal payments on capital lease obligations	0	0
Net cash used in financing activities	0	0
Foreign exchange effect on cash and cash equivalents	(254)	0
Net increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents, beginning of period	0	0		$ 0
Cash and cash equivalents, end of period	$ 0	$ 0
[1]	As Restated